,terms,label,prediction,extended_terms,extended_prediction
0,"p value """,arms;measures,measures,"p value """,measures
1,placebo,arms;measures,arms,placebo,arms
2,gemfibrozil,arms;measures,characteristic_name,gemfibrozil,characteristic_name
3,risk reduction ( nmbr % cl ),arms;measures,measures,risk reduction ( nmbr % cl ),measures
4,p value,arms;measures,measures,p value,measures
5,stent plus abciximab,arms;measures,arms,stent plus abciximab,arms
6,"balloon angioplasty plus abciximab """,arms;measures,arms,"balloon angioplasty plus abciximab """,arms
7,p *,arms;measures,characteristic_name,p *,characteristic_name
8,pt,arms;measures,measures,pt,measures
9,balloon angioplasty plus abciximab,arms;measures,arms,balloon angioplasty plus abciximab,arms
10,stent plus placebo,arms;measures,arms,stent plus placebo,arms
11,no . of patients,measures;arms,characteristic_level,no . of patients,characteristic_level
12,irofiban,measures;arms,characteristic_name,irofiban,characteristic_name
13,abciximab,measures;arms,arms,abciximab,arms
14,"abciximab """,measures;arms,arms,"abciximab """,arms
15,ticlopidine ( n = nmbr ),arms;measures,characteristic_level,ticlopidine ( n = nmbr ),characteristic_level
16,p,arms;measures,characteristic_name,p,characteristic_name
17,clopidogrel ( n = nmbr ),arms;measures,arms,clopidogrel ( n = nmbr ),arms
18,"ticlopidine ( n = nmbr ) """,arms;measures,characteristic_level,"ticlopidine ( n = nmbr ) """,characteristic_level
19,"warfarin group ( n = nmbr ) """,arms;measures,arms,"warfarin group ( n = nmbr ) """,arms
21,placebo group ( n = nmbr ),arms;measures,arms,placebo group ( n = nmbr ),arms
22,warfarin group ( n = nmbr ),arms;measures,arms,warfarin group ( n = nmbr ),arms
23,"placebo group """,arms;measures;p-interaction,arms,"placebo group """,arms
24,p value for interaction^,arms;measures;p-interaction,measures,p value for interaction^,measures
25,hazard ratio ( nmbr % ci ) *,arms;measures;p-interaction,measures,hazard ratio ( nmbr % ci ) *,measures
26,warfarin group,arms;measures;p-interaction,arms,warfarin group,arms
27,placebo group,arms;measures;p-interaction,arms,placebo group,arms
28,rr ( nmbr % cl ),arms;measures,measures,rr ( nmbr % cl ),measures
29,"non - calcium antagonist strategy ( ncas ) ( events / n ) """,arms;measures,arms,"non - calcium antagonist strategy ( ncas ) ( events / n ) """,arms
30,non - calcium antagonist strategy ( ncas ) ( events / n ),arms;measures,arms,non - calcium antagonist strategy ( ncas ) ( events / n ),arms
31,calcium antagonist strategy ( cas ) ( events / n ),arms;measures,arms,calcium antagonist strategy ( cas ) ( events / n ),arms
32,gfr ( ml / min per nmbr . nmbr nr ),measures;arms,characteristic_level,gfr ( ml / min per nmbr . nmbr nr ),characteristic_level
33,esrd on losartan ( % ),measures;arms,outcomes,esrd on losartan ( % ),outcomes
34,chf on placebo ( % ),measures;arms,arms,chf on placebo ( % ),arms
35,esrd on placebo ( % ),measures;arms,arms,esrd on placebo ( % ),arms
36,p ( losartan versus placebo ),measures;arms,arms,p ( losartan versus placebo ),arms
37,risk reduction ( % ; nmbr % ci ),measures;arms,measures,risk reduction ( % ; nmbr % ci ),measures
38,chf on losartan ( % ),measures;arms,measures,chf on losartan ( % ),measures
40,"p ( losartan versus placebo ) """,measures;arms,arms,"p ( losartan versus placebo ) """,arms
41,"beta - carotene ( n = nmbr , nmbr )",arms;measures,arms,"beta - carotene ( n = nmbr , nmbr )",arms
42,"nmbr % ci """,arms;measures,measures,"nmbr % ci """,measures
43,"placebo ( n = nmbr , nmbr )",arms;measures,arms,"placebo ( n = nmbr , nmbr )",arms
44,rr *,arms;measures,characteristic_name,rr *,characteristic_name
45,nmbr % ci,arms;measures,measures,nmbr % ci,measures
51,p interaction,arms;measures,characteristic_name,p interaction,characteristic_name
53,beta - carotene,arms;measures,arms,beta - carotene,arms
58,rr ( nmbr % ci ),arms;measures,measures,rr ( nmbr % ci ),measures
59,pla,arms;measures,arms,pla,arms
60,asp,arms;measures,characteristic_name,asp,characteristic_name
62,patients with end point,arms;measures,measures,patients with end point,measures
63,"patients with end point """,arms;measures,measures,"patients with end point """,measures
64,pbo,arms;p-interaction,arms,pbo,arms
65,"p - value * ' ' """,arms;p-interaction,measures,"p - value * ' ' """,measures
66,eze nmbr mg,arms;p-interaction,arms,eze nmbr mg,arms
67,p - value * ' ',arms;p-interaction,measures,p - value * ' ',measures
68,"placebo ( n = nmbr nmbr ) """,arms;p-interaction,arms,"placebo ( n = nmbr nmbr ) """,arms
69,placebo ( n = nmbr nmbr ),arms;p-interaction,arms,placebo ( n = nmbr nmbr ),arms
70,aspirin ( n = nmbr nmbr ),arms;p-interaction,characteristic_level,aspirin ( n = nmbr nmbr ),characteristic_level
71,total ( n = nmbr nmbr ),arms;p-interaction,arms,total ( n = nmbr nmbr ),arms
72,p value,arms;p-interaction,measures,p value,measures
73,lips,other;outcomes,characteristic_name,lips,characteristic_name
74,cards,other;outcomes,characteristic_name,cards,characteristic_name
75,woscops,other;outcomes,characteristic_name,woscops,characteristic_name
76,total,other;outcomes,arms,total,arms
77,hps,other;outcomes,characteristic_name,hps,characteristic_name
78,gissi prevention nmbr / nmbr - nmbr / nmbr,other;outcomes,characteristic_level,gissi prevention nmbr / nmbr - nmbr / nmbr,characteristic_level
79,alert,other;outcomes,characteristic_name,alert,characteristic_name
80,lipid,other;outcomes,characteristic_name,lipid,characteristic_name
81,afcaps /,other;outcomes,characteristic_name,afcaps /,characteristic_name
82,nmbr,other;outcomes,characteristic_level,nmbr,characteristic_level
83,post - cabg,other;outcomes,characteristic_level,post - cabg,characteristic_level
84,allhat - llt,other;outcomes,characteristic_name,allhat - llt,characteristic_name
85,care,other;outcomes,arms,care,arms
86,prosper,other;outcomes,characteristic_name,prosper,characteristic_name
87,ascot - lla,other;outcomes,characteristic_name,ascot - lla,characteristic_name
88,"post - cabg """,other;outcomes,characteristic_level,"post - cabg """,characteristic_level
89,baseline history of vascular disease ( % ),measures;characteristic_name,characteristic_name,baseline history of vascular disease ( % ),characteristic_name
90,"baseline history of vascular disease ( % ) """,measures;characteristic_name,characteristic_name,"baseline history of vascular disease ( % ) """,characteristic_name
91,heterogeneity / trend test,arms;other,characteristic_name,heterogeneity / trend test,characteristic_name
92,"events treatment ( nmbr ) """,arms;other,measures,"events treatment ( nmbr ) """,measures
93,events treatment ( nmbr ),arms;other,measures,events treatment ( nmbr ),measures
94,rr ( cl ),arms;other,measures,rr ( cl ),measures
95,( % ) control ( nmbr ),arms;other,arms,( % ) control ( nmbr ),arms
96,heterogeneity / trend test,arms;other;measures,characteristic_name,heterogeneity / trend test,characteristic_name
97,"events treatment ( nmbr ) """,arms;other;measures,measures,"events treatment ( nmbr ) """,measures
98,events treatment ( nmbr ),arms;other;measures,measures,events treatment ( nmbr ),measures
99,rr ( cl ),arms;other;measures,measures,rr ( cl ),measures
100,( % ) control ( nmbr ),arms;other;measures,arms,( % ) control ( nmbr ),arms
101,white,measures;characteristic_level,characteristic_level,white,characteristic_level
102,"white """,measures;characteristic_level,characteristic_level,"white """,characteristic_level
103,asian,measures;characteristic_level,characteristic_level,asian,characteristic_level
104,black,measures;characteristic_level,characteristic_level,black,characteristic_level
105,hispanic,measures;characteristic_level,characteristic_level,hispanic,characteristic_level
106,pre - specified hr ( nmbr % cl ),arms;measures,measures,pre - specified hr ( nmbr % cl ),measures
108,adjusted hr ( nmbr % cl ),arms;measures,measures,adjusted hr ( nmbr % cl ),measures
109,"adjusted hr ( nmbr % cl ) """,arms;measures,measures,"adjusted hr ( nmbr % cl ) """,measures
110,losartan,arms;measures,characteristic_name,losartan,characteristic_name
111,"nmbr - year rates in placebo groups """,measures;p-interaction,arms,"nmbr - year rates in placebo groups """,arms
112,| interactior nmbr p,measures;p-interaction,characteristic_level,| interactior nmbr p,characteristic_level
113,number of patients,measures;p-interaction,measures,number of patients,measures
114,nmbr - year rates in placebo groups,measures;p-interaction,arms,nmbr - year rates in placebo groups,arms
115,p value for interaction,measures;p-interaction,measures,p value for interaction,measures
116,hr ( nmbr % ci ),measures;p-interaction,measures,hr ( nmbr % ci ),measures
117,"p value for interaction """,measures;p-interaction,measures,"p value for interaction """,measures
118,metabolic syndrome *,characteristic_level;arms,characteristic_level,metabolic syndrome *,characteristic_level
119,neither pbo + statin eze + statin,characteristic_level;arms,arms,neither pbo + statin eze + statin,arms
120,"metabolic syndrome * """,characteristic_level;arms,characteristic_level,"metabolic syndrome * """,characteristic_level
121,diabetes mellitus,characteristic_level;arms,characteristic_level,diabetes mellitus,characteristic_level
123,"placebo ( n = nmbr ) """,arms;measures,arms,"placebo ( n = nmbr ) """,arms
124,abciximab ( n = nmbr ),arms;measures,arms,abciximab ( n = nmbr ),arms
125,placebo ( n = nmbr ),arms;measures,arms,placebo ( n = nmbr ),arms
130,etoricoxib,measures;arms,arms,etoricoxib,arms
131,"diclofenac """,measures;arms,arms,"diclofenac """,arms
132,diclofenac,measures;arms,arms,diclofenac,arms
133,history of upper,characteristic_name;characteristic_level,characteristic_name,history of upper,characteristic_name
134,> nmbr years,characteristic_name;characteristic_level,characteristic_level,> nmbr years,characteristic_level
135,methotrexate use,characteristic_name;characteristic_level,characteristic_name,methotrexate use,characteristic_name
136,ppi use,characteristic_name;characteristic_level,characteristic_name,ppi use,characteristic_name
137,low - dose aspirin use,characteristic_name;characteristic_level,characteristic_name,low - dose aspirin use,characteristic_name
138,other dmard use,characteristic_name;characteristic_level,characteristic_name,other dmard use,characteristic_name
139,cox - nmbr selective inhibitor use,characteristic_name;characteristic_level,characteristic_level,cox - nmbr selective inhibitor use,characteristic_level
140,sex ( female ),characteristic_name;characteristic_level,characteristic_name,sex ( female ),characteristic_name
141,> nmbr to < nmbr years,characteristic_name;characteristic_level,characteristic_level,> nmbr to < nmbr years,characteristic_level
142,traditional nsaid use,characteristic_name;characteristic_level,characteristic_name,traditional nsaid use,characteristic_name
143,systemic corticosteroid use,characteristic_name;characteristic_level,characteristic_name,systemic corticosteroid use,characteristic_name
144,"cox - nmbr selective inhibitor use """,characteristic_name;characteristic_level,characteristic_level,"cox - nmbr selective inhibitor use """,characteristic_level
145,age ( years ),characteristic_name;characteristic_level,characteristic_name,age ( years ),characteristic_name
146,rheumatoid arthritis,characteristic_name;characteristic_level,characteristic_name,rheumatoid arthritis,characteristic_name
147,osteoarthritis,characteristic_name;characteristic_level,characteristic_name,osteoarthritis,characteristic_name
148,< nmbr years,characteristic_name;characteristic_level,characteristic_level,< nmbr years,characteristic_level
149,cigarette smoker,characteristic_name;characteristic_level,characteristic_level,cigarette smoker,characteristic_level
150,"etoricoxib """,arms;measures,arms,"etoricoxib """,arms
151,hazard ratio ( nmbr % ci ),arms;measures,measures,hazard ratio ( nmbr % ci ),measures
152,etoricoxib,arms;measures,arms,etoricoxib,arms
153,diclofenac,arms;measures,arms,diclofenac,arms
154,interaction p,arms;measures;p-interaction,characteristic_name,interaction p,characteristic_name
155,control ( n = nmbr ),arms;measures;p-interaction,arms,control ( n = nmbr ),arms
156,epa ( n = nmbr ),arms;measures;p-interaction,arms,epa ( n = nmbr ),arms
157,"hazard ratio ( nmbr % cl ) """,arms;measures;p-interaction,measures,"hazard ratio ( nmbr % cl ) """,measures
158,hazard ratio ( nmbr % cl ),arms;measures;p-interaction,measures,hazard ratio ( nmbr % cl ),measures
159,hyperlipidemia,characteristic_name;characteristic_level,arms,hyperlipidemia,arms
160,unstable angina,characteristic_name;characteristic_level,arms,unstable angina,arms
161,statin,characteristic_name;characteristic_level,arms,statin,arms
162,"age , median ( iqr ) , y",characteristic_name;characteristic_level,characteristic_level,"age , median ( iqr ) , y",characteristic_level
163,hypertension,characteristic_name;characteristic_level,characteristic_level,hypertension,characteristic_level
164,glycoprotein llb / llla receptor inhibitor,characteristic_name;characteristic_level,characteristic_level,glycoprotein llb / llla receptor inhibitor,characteristic_level
165,current smoker,characteristic_name;characteristic_level,characteristic_level,current smoker,characteristic_level
166,aspirin,characteristic_name;characteristic_level,arms,aspirin,arms
167,diabetes mellitus,characteristic_name;characteristic_level,characteristic_level,diabetes mellitus,characteristic_level
168,p - blocker,characteristic_name;characteristic_level,characteristic_level,p - blocker,characteristic_level
169,prior ml,characteristic_name;characteristic_level,characteristic_level,prior ml,characteristic_level
170,female sex,characteristic_name;characteristic_level,characteristic_name,female sex,characteristic_name
171,st - segment depression > nmbr . nmbr mv,characteristic_name;characteristic_level,characteristic_level,st - segment depression > nmbr . nmbr mv,characteristic_level
172,prior coronary revascularization,characteristic_name;characteristic_level,characteristic_level,prior coronary revascularization,characteristic_level
173,ace inhibitor or angiotensin ii receptor blocker,characteristic_name;characteristic_level,characteristic_level,ace inhibitor or angiotensin ii receptor blocker,characteristic_level
174,estimated creatinine clearance < nmbr ml / mint,characteristic_name;characteristic_level,characteristic_name,estimated creatinine clearance < nmbr ml / mint,characteristic_name
175,"female sex """,characteristic_name;characteristic_level,characteristic_name,"female sex """,characteristic_name
176,non - st - elevation ml,characteristic_name;characteristic_level,characteristic_level,non - st - elevation ml,characteristic_level
177,"weight , median ( iqr ) , kg",characteristic_name;characteristic_level,characteristic_level,"weight , median ( iqr ) , kg",characteristic_level
178,age > nmbr y,characteristic_name;characteristic_level,characteristic_name,age > nmbr y,characteristic_name
179,thienopyridine,characteristic_name;characteristic_level,arms,thienopyridine,arms
180,"body mass index , median ( iqr )",characteristic_name;characteristic_level,characteristic_name,"body mass index , median ( iqr )",characteristic_name
181,other,characteristic_name;characteristic_level,characteristic_level,other,characteristic_level
182,white race,characteristic_name;characteristic_level,characteristic_name,white race,characteristic_name
183,prior heart failure,characteristic_name;characteristic_level,characteristic_name,prior heart failure,characteristic_name
184,heparin,characteristic_name;characteristic_level,characteristic_level,heparin,characteristic_level
185,nmbr - nmbr,characteristic_name;characteristic_level,characteristic_level,nmbr - nmbr,characteristic_level
186,"time from onset of pain to randomization , median ( iqr ) , h",characteristic_name;characteristic_level,characteristic_name,"time from onset of pain to randomization , median ( iqr ) , h",characteristic_name
187,coronary angiography during the index hospitalization,characteristic_name;characteristic_level,characteristic_name,coronary angiography during the index hospitalization,characteristic_name
188,placebo group ( n = nmbr ) f,arms;measures,arms,placebo group ( n = nmbr ) f,arms
189,certolizumab group ( n = nmbr ),arms;measures,arms,certolizumab group ( n = nmbr ),arms
190,"certolizumab group ( n = nmbr ) """,arms;measures,arms,"certolizumab group ( n = nmbr ) """,arms
192,rrr ( nmbr % cl ),arms;measures,measures,rrr ( nmbr % cl ),measures
193,p - valuea,arms;measures,characteristic_name,p - valuea,characteristic_name
195,"placebo """,arms;measures,arms,"placebo """,arms
196,interactionnmbr,arms;measures,characteristic_name,interactionnmbr,characteristic_name
198,"nmbr . nmbr """,arms;measures,characteristic_level,"nmbr . nmbr """,characteristic_level
199,nmbr . nmbr,arms;measures,characteristic_level,nmbr . nmbr,characteristic_level
200,nmbr . nmbr ( nmbr . nmbr - nmbr . nmbr ),arms;measures,characteristic_level,nmbr . nmbr ( nmbr . nmbr - nmbr . nmbr ),characteristic_level
201,p,measures;other,characteristic_name,p,characteristic_name
202,id genotype,measures;other,arms,id genotype,arms
203,"id genotype """,measures;other,arms,"id genotype """,arms
204,"adjustednmbr risk reduction losartan vs placebo ( nmbr % cl ) """,arms;measures;p-interaction,measures,"adjustednmbr risk reduction losartan vs placebo ( nmbr % cl ) """,measures
205,"placebo , n / n ( % )",arms;measures;p-interaction,arms,"placebo , n / n ( % )",arms
206,"losartan , n / n ( % )",arms;measures;p-interaction,characteristic_name,"losartan , n / n ( % )",characteristic_name
207,f * >,arms;measures;p-interaction,characteristic_name,f * >,characteristic_name
208,adjustednmbr risk reduction losartan vs placebo ( nmbr % cl ),arms;measures;p-interaction,measures,adjustednmbr risk reduction losartan vs placebo ( nmbr % cl ),measures
209,amlodipine / valsartan nmbr / nmbr mg ( n = nmbr ),arms;other,arms,amlodipine / valsartan nmbr / nmbr mg ( n = nmbr ),arms
210,"amlodipine / valsartan nmbr / nmbr mg ( n = nmbri ) """,arms;other,arms,"amlodipine / valsartan nmbr / nmbr mg ( n = nmbri ) """,arms
211,amlodipine / valsartan nmbr / nmbr mg ( n = nmbri ),arms;other,arms,amlodipine / valsartan nmbr / nmbr mg ( n = nmbri ),arms
212,total study population ( n = nmbr ),arms;other,other,total study population ( n = nmbr ),other
213,"aspirin ( n = nmbr nmbr ) """,arms;measures,characteristic_level,"aspirin ( n = nmbr nmbr ) """,characteristic_level
214,placebo ( n = nmbr nmbr ),arms;measures,arms,placebo ( n = nmbr nmbr ),arms
215,aspirin ( n = nmbr nmbr ),arms;measures,characteristic_level,aspirin ( n = nmbr nmbr ),characteristic_level
217,aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years ),arms;measures,characteristic_level,aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years ),characteristic_level
218,placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years ),arms;measures,arms,placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years ),arms
219,"placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years ) """,arms;measures,arms,"placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years ) """,arms
220,hazard ratio * ( nmbr % ci ),arms;measures,measures,hazard ratio * ( nmbr % ci ),measures
222,lumbar spine bmd t - score,characteristic_name;characteristic_level,characteristic_name,lumbar spine bmd t - score,characteristic_name
223,serum pnmbrnp ( ^g / liter ),characteristic_name;characteristic_level,characteristic_level,serum pnmbrnp ( ^g / liter ),characteristic_level
224,< nmbr yr since menopause,characteristic_name;characteristic_level,characteristic_level,< nmbr yr since menopause,characteristic_level
225,> nmbr yr since menopause,characteristic_name;characteristic_level,characteristic_level,> nmbr yr since menopause,characteristic_level
226,serum ctx ( ng / ml ),characteristic_name;characteristic_level,characteristic_level,serum ctx ( ng / ml ),characteristic_level
227,bodymass index ( kg / mnmbr ),characteristic_name;characteristic_level,characteristic_name,bodymass index ( kg / mnmbr ),characteristic_name
228,age ( yr ),characteristic_name;characteristic_level,characteristic_level,age ( yr ),characteristic_level
229,"< nmbr yr since menopause """,characteristic_name;characteristic_level,characteristic_level,"< nmbr yr since menopause """,characteristic_level
230,serum trap - nmbrb ( u / liter ),characteristic_name;characteristic_level,characteristic_name,serum trap - nmbrb ( u / liter ),characteristic_name
231,years since menopause,characteristic_name;characteristic_level,characteristic_level,years since menopause,characteristic_level
232,"denosumab ( n = nmbr ) """,arms;measures,characteristic_level,"denosumab ( n = nmbr ) """,characteristic_level
233,all ( n = nmbr ),arms;measures,characteristic_level,all ( n = nmbr ),characteristic_level
234,denosumab ( n = nmbr ),arms;measures,characteristic_level,denosumab ( n = nmbr ),characteristic_level
236,crp ( mg / dl ) < nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level,crp ( mg / dl ) < nmbr . nmbr,characteristic_level
237,current smoker yes,characteristic_name;characteristic_level,characteristic_level,current smoker yes,characteristic_level
238,bmi ( kg / mnmbr ) < nmbr,characteristic_name;characteristic_level,characteristic_level,bmi ( kg / mnmbr ) < nmbr,characteristic_level
239,ldl - c ( mg / dl ) < nmbr,characteristic_name;characteristic_level,characteristic_level,ldl - c ( mg / dl ) < nmbr,characteristic_level
240,female,characteristic_name;characteristic_level,characteristic_level,female,characteristic_level
241,ale < nmbr,characteristic_name;characteristic_level,characteristic_level,ale < nmbr,characteristic_level
242,no,characteristic_name;characteristic_level,measures,no,measures
243,"> nmbr """,characteristic_name;characteristic_level,characteristic_level,"> nmbr """,characteristic_level
244,nmbr . nmbr - nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level,nmbr . nmbr - nmbr . nmbr,characteristic_level
245,sbp ( mmhg ) < nmbr,characteristic_name;characteristic_level,arms,sbp ( mmhg ) < nmbr,arms
247,age ( yrs ) < nmbr,characteristic_name;characteristic_level,characteristic_level,age ( yrs ) < nmbr,characteristic_level
248,non - hdl ( mg / dl ) < nmbr,characteristic_name;characteristic_level,characteristic_level,non - hdl ( mg / dl ) < nmbr,characteristic_level
249,gender male,characteristic_name;characteristic_level,characteristic_level,gender male,characteristic_level
250,> nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level,> nmbr . nmbr,characteristic_level
251,egfr < nmbr,characteristic_name;characteristic_level,characteristic_level,egfr < nmbr,characteristic_level
252,> nmbr,characteristic_name;characteristic_level,characteristic_level,> nmbr,characteristic_level
253,no epa group n = nmbr,arms;measures,arms,no epa group n = nmbr,arms
254,epa group n = nmbr,arms;measures,arms,epa group n = nmbr,arms
255,"epa group n = nmbr """,arms;measures,arms,"epa group n = nmbr """,arms
257,no epa group no . of events ( % ),measures;p-interaction,arms,no epa group no . of events ( % ),arms
258,"p value """,measures;p-interaction,measures,"p value """,measures
259,"hr , nmbr % cl",measures;p-interaction,measures,"hr , nmbr % cl",measures
260,epa group no . of events ( % ),measures;p-interaction,arms,epa group no . of events ( % ),arms
261,p value,measures;p-interaction,measures,p value,measures
262,"placebo group ( n = nmbr ) """,measures;arms,arms,"placebo group ( n = nmbr ) """,arms
263,metoprolol group ( n = nmbr ),measures;arms,arms,metoprolol group ( n = nmbr ),arms
264,placebo group ( n = nmbr ),measures;arms,arms,placebo group ( n = nmbr ),arms
265,p *,arms;p-interaction,characteristic_name,p *,characteristic_name
266,"valsartan ( n = nmbr ) """,arms;p-interaction,arms,"valsartan ( n = nmbr ) """,arms
267,valsartan ( n = nmbr ),arms;p-interaction,arms,valsartan ( n = nmbr ),arms
268,valsartan / hctz ( n = nmbr ),arms;p-interaction,arms,valsartan / hctz ( n = nmbr ),arms
269,p *,p-interaction;arms,characteristic_name,p *,characteristic_name
270,"valsartan / hctz , n / n ( % ) """,p-interaction;arms,arms,"valsartan / hctz , n / n ( % ) """,arms
271,"valsartan , n / n ( % )",p-interaction;arms,arms,"valsartan , n / n ( % )",arms
272,"valsartan / hctz , n / n ( % )",p-interaction;arms,arms,"valsartan / hctz , n / n ( % )",arms
273,valsartan,arms;p-interaction,arms,valsartan,arms
274,p,arms;p-interaction,characteristic_name,p,characteristic_name
275,valsartan / hctz,arms;p-interaction,arms,valsartan / hctz,arms
276,"valsartan / hctz """,arms;p-interaction,arms,"valsartan / hctz """,arms
277,usual care ( n = nmbra ),arms;measures,arms,usual care ( n = nmbra ),arms
278,"usual care ( n = nmbrla ) """,arms;measures,arms,"usual care ( n = nmbrla ) """,arms
279,proactive intervention ( n = nmbra ),arms;measures,characteristic_name,proactive intervention ( n = nmbra ),characteristic_name
280,usual care ( n = nmbrla ),arms;measures,arms,usual care ( n = nmbrla ),arms
281,p valuenmbr,arms;measures,characteristic_name,p valuenmbr,characteristic_name
282,"standard control ( n = nmbr ) no . of patients ( percent ) """,arms;measures,measures,"standard control ( n = nmbr ) no . of patients ( percent ) """,measures
283,intensive control ( n = nmbr ) no . of patients ( percent ),arms;measures,measures,intensive control ( n = nmbr ) no . of patients ( percent ),measures
284,standard control ( n = nmbr ) no . of patients ( percent ),arms;measures,measures,standard control ( n = nmbr ) no . of patients ( percent ),measures
285,relative risk reduction ( nmbr % cl ) percent,arms;measures,measures,relative risk reduction ( nmbr % cl ) percent,measures
286,verapamil sr n = nmbr no . ( % ),arms;measures,arms,verapamil sr n = nmbr no . ( % ),arms
287,hr ( nmbr % cl ),arms;measures,measures,hr ( nmbr % cl ),measures
288,"atenolol n = nmbr no . ( % ) """,arms;measures,arms,"atenolol n = nmbr no . ( % ) """,arms
289,atenolol n = nmbr no . ( % ),arms;measures,arms,atenolol n = nmbr no . ( % ),arms
290,"aspirin - erdp clopidogrel no . of patients / total no . """,arms;measures,arms,"aspirin - erdp clopidogrel no . of patients / total no . """,arms
291,aspirin - erdp clopidogrel no . of patients / total no .,arms;measures,arms,aspirin - erdp clopidogrel no . of patients / total no .,arms
292,hr ( nmbr % cl ) *,arms;measures,measures,hr ( nmbr % cl ) *,measures
293,placebo events / patients ( % ),arms;measures,measures,placebo events / patients ( % ),measures
294,"placebo events / patients ( % ) """,arms;measures,measures,"placebo events / patients ( % ) """,measures
295,rosuvastatin events / patients ( % ),arms;measures,measures,rosuvastatin events / patients ( % ),measures
299,n - nmbr pufa events / patients ( % ),arms;measures,measures,n - nmbr pufa events / patients ( % ),measures
300,p inleraclion,arms;measures;p-interaction,characteristic_name,p inleraclion,characteristic_name
301,aspirin group,arms;measures;p-interaction,arms,aspirin group,arms
302,"rr ( nmbr % ci ) * """,arms;measures;p-interaction,measures,"rr ( nmbr % ci ) * """,measures
303,rr ( nmbr % ci ) *,arms;measures;p-interaction,measures,rr ( nmbr % ci ) *,measures
305,"irbesartan """,arms;p-interaction,arms,"irbesartan """,arms
306,p value for interaction,arms;p-interaction,measures,p value for interaction,measures
307,irbesartan,arms;p-interaction,arms,irbesartan,arms
308,placebo,arms;p-interaction,arms,placebo,arms
309,india,characteristic_name;characteristic_level,characteristic_level,india,characteristic_level
310,hbanmbrc ( % ) all countries,characteristic_name;characteristic_level,characteristic_name,hbanmbrc ( % ) all countries,characteristic_name
311,"india """,characteristic_name;characteristic_level,characteristic_level,"india """,characteristic_level
312,china,characteristic_name;characteristic_level,arms,china,arms
313,all countries,characteristic_name;characteristic_level,arms,all countries,arms
314,korea,characteristic_name;characteristic_level,arms,korea,arms
315,hydochlorothiazide ( n = nmbr ),arms;measures,characteristic_level,hydochlorothiazide ( n = nmbr ),characteristic_level
316,aliskiren ( n = nmbr ),arms;measures,arms,aliskiren ( n = nmbr ),arms
317,"hydochlorothiazide ( n = nmbr ) """,arms;measures,characteristic_level,"hydochlorothiazide ( n = nmbr ) """,characteristic_level
323,value for nteraction,measures;p-interaction,measures,value for nteraction,measures
324,"value for nteraction """,measures;p-interaction,measures,"value for nteraction """,measures
325,hr,arms;measures,measures,hr,measures
326,ranozaline,arms;measures,characteristic_name,ranozaline,characteristic_name
327,"ranozaline """,arms;measures,characteristic_name,"ranozaline """,characteristic_name
329,"placebo """,arms;p-interaction,arms,"placebo """,arms
333,total,arms;measures,arms,total,arms
334,fp nmbr mg,arms;measures,arms,fp nmbr mg,arms
336,sfc nmbr mg / nmbr mg,arms;measures,arms,sfc nmbr mg / nmbr mg,arms
338,sal nmbr mg,arms;measures,arms,sal nmbr mg,arms
339,triglyceride ( median : mg / dl ) a [nmbr - nmbr percentile],outcomes;measures,characteristic_level,triglyceride ( median : mg / dl ) a [nmbr - nmbr percentile],characteristic_level
340,ldl - cholesterol ( mg / dl ),outcomes;measures,characteristic_name,ldl - cholesterol ( mg / dl ),characteristic_name
341,hdl - cholesterol ( mg / dl ),outcomes;measures,characteristic_name,hdl - cholesterol ( mg / dl ),characteristic_name
342,diastolic fmmhff ' ),outcomes;measures,characteristic_name,diastolic fmmhff ' ),characteristic_name
343,total cholesterol ( mg / dl ),outcomes;measures,arms,total cholesterol ( mg / dl ),arms
344,systolic ( mmhg ),outcomes;measures,arms,systolic ( mmhg ),arms
345,epa ( mol % ),outcomes;measures,arms,epa ( mol % ),arms
346,fpg ( mg / dl ),outcomes;measures,outcomes,fpg ( mg / dl ),outcomes
347,"hba , c ( % )",outcomes;measures,characteristic_name,"hba , c ( % )",characteristic_name
348,"systolic ( mmhg ) """,outcomes;measures,arms,"systolic ( mmhg ) """,arms
349,non - epa number of <,arms;measures,arms,non - epa number of <,arms
350,"non - epa number of < """,arms;measures,arms,"non - epa number of < """,arms
352,epa hr events ( % ),arms;measures,measures,epa hr events ( % ),measures
354,"p value for trend """,characteristic_name;p-interaction,measures,"p value for trend """,measures
355,mmse score,characteristic_name;p-interaction,characteristic_name,mmse score,characteristic_name
356,p value for trend,characteristic_name;p-interaction,measures,p value for trend,measures
357,mmse > nmbr,characteristic_name;characteristic_level,characteristic_name,mmse > nmbr,characteristic_name
358,all participants,characteristic_name;characteristic_level,measures,all participants,measures
359,mmse nmbr - nmbr,characteristic_name;characteristic_level,arms,mmse nmbr - nmbr,arms
360,mmse < nmbr,characteristic_name;characteristic_level,characteristic_name,mmse < nmbr,characteristic_name
361,"all participants """,characteristic_name;characteristic_level,measures,"all participants """,measures
362,no history of paroxysmal af,characteristic_level;characteristic_name,characteristic_name,no history of paroxysmal af,characteristic_name
363,history of paroxysmal af,characteristic_level;characteristic_name,characteristic_name,history of paroxysmal af,characteristic_name
364,total cholesterolnmbr > nmbr mg / dl,characteristic_level;characteristic_name,arms,total cholesterolnmbr > nmbr mg / dl,arms
365,nyha ii,characteristic_level;characteristic_name,characteristic_level,nyha ii,characteristic_level
366,nyha lll - iv,characteristic_level;characteristic_name,characteristic_level,nyha lll - iv,characteristic_level
367,diabetes,characteristic_level;characteristic_name,characteristic_level,diabetes,characteristic_level
368,ischemic aetiology,characteristic_level;characteristic_name,outcomes,ischemic aetiology,outcomes
369,egfr > nmbr ( ml / min / nmbr . nmbr mnmbr ),characteristic_level;characteristic_name,characteristic_level,egfr > nmbr ( ml / min / nmbr . nmbr mnmbr ),characteristic_level
370,"no history of paroxysmal af """,characteristic_level;characteristic_name,characteristic_name,"no history of paroxysmal af """,characteristic_name
371,lvef > nmbr %,characteristic_level;characteristic_name,characteristic_level,lvef > nmbr %,characteristic_level
372,age > nmbr yearsnmbr,characteristic_level;characteristic_name,characteristic_name,age > nmbr yearsnmbr,characteristic_name
373,age < nmbr yearsnmbr,characteristic_level;characteristic_name,characteristic_name,age < nmbr yearsnmbr,characteristic_name
374,egfr < nmbr ( ml / min / nmbr . nmbr mnmbr ),characteristic_level;characteristic_name,characteristic_level,egfr < nmbr ( ml / min / nmbr . nmbr mnmbr ),characteristic_level
375,no diabetes,characteristic_level;characteristic_name,characteristic_level,no diabetes,characteristic_level
376,total cholesterolnmbr < nmbr mg / dl,characteristic_level;characteristic_name,arms,total cholesterolnmbr < nmbr mg / dl,arms
377,non - ischaemic aetiology,characteristic_level;characteristic_name,characteristic_level,non - ischaemic aetiology,characteristic_level
378,lvef < nmbr %,characteristic_level;characteristic_name,characteristic_level,lvef < nmbr %,characteristic_level
379,p value for heterogeneity,arms;p-interaction,measures,p value for heterogeneity,measures
380,"fluvastatin ( n = nmbr ) """,arms;p-interaction,characteristic_level,"fluvastatin ( n = nmbr ) """,characteristic_level
381,placebo ( n = nmbr ),arms;p-interaction,arms,placebo ( n = nmbr ),arms
382,fluvastatin ( n = nmbr ),arms;p-interaction,characteristic_level,fluvastatin ( n = nmbr ),characteristic_level
383,primary pci ( n = nmbr ),arms;measures,outcomes,primary pci ( n = nmbr ),outcomes
384,reteplase / abciximab - facilitated pci ( n = nmbr ),arms;measures,arms,reteplase / abciximab - facilitated pci ( n = nmbr ),arms
385,abciximab - facilitated pci ( n = nmbr ),arms;measures,arms,abciximab - facilitated pci ( n = nmbr ),arms
386,"primary pci ( n = nmbr ) """,arms;measures,outcomes,"primary pci ( n = nmbr ) """,outcomes
388,subgroup p - valuenmbr,arms;measures;p-interaction,characteristic_level,subgroup p - valuenmbr,characteristic_level
389,nmbr % cinmbr,arms;measures;p-interaction,characteristic_level,nmbr % cinmbr,characteristic_level
390,placebo n ( rate ) nmbr,arms;measures;p-interaction,arms,placebo n ( rate ) nmbr,arms
391,interaction p - valuenmbr,arms;measures;p-interaction,characteristic_name,interaction p - valuenmbr,characteristic_name
392,rosuvastatin n ( rate ) nmbr,arms;measures;p-interaction,measures,rosuvastatin n ( rate ) nmbr,measures
393,"hazard rationmbr """,arms;measures;p-interaction,measures,"hazard rationmbr """,measures
394,hazard rationmbr,arms;measures;p-interaction,measures,hazard rationmbr,measures
395,"rosuvastatin , n ( rate )",arms;measures;p-interaction,measures,"rosuvastatin , n ( rate )",measures
396,"p , interaction !",arms;measures;p-interaction,characteristic_name,"p , interaction !",characteristic_name
397,"p , subgroup *",arms;measures;p-interaction,characteristic_level,"p , subgroup *",characteristic_level
398,"placebo , n ( rate )",arms;measures;p-interaction,arms,"placebo , n ( rate )",arms
399,hr ( nmbr % cl ),arms;measures;p-interaction,measures,hr ( nmbr % cl ),measures
400,"p , subgroup * """,arms;measures;p-interaction,characteristic_level,"p , subgroup * """,characteristic_level
401,all patients ( n = nmbr ),arms;measures,characteristic_level,all patients ( n = nmbr ),characteristic_level
402,p valued,arms;measures,characteristic_name,p valued,characteristic_name
403,infliximab ( n = nmbr ),arms;measures,arms,infliximab ( n = nmbr ),arms
404,combination therapy ( n = nmbr ),arms;measures,arms,combination therapy ( n = nmbr ),arms
405,"azathioprine ( n = nmbr ) """,arms;measures,characteristic_level,"azathioprine ( n = nmbr ) """,characteristic_level
406,azathioprine ( n = nmbr ),arms;measures,characteristic_level,azathioprine ( n = nmbr ),characteristic_level
407,"control """,arms;measures,arms,"control """,arms
408,control,arms;measures,arms,control,arms
409,difference,arms;measures,measures,difference,measures
410,mean yearly decline,measures;arms,measures,mean yearly decline,measures
411,"mean yearly decline """,measures;arms,measures,"mean yearly decline """,measures
412,control,measures;arms,arms,control,arms
413,tiotropium,measures;arms,arms,tiotropium,arms
414,events,arms;measures,measures,events,measures
415,"n """,arms;measures,characteristic_name,"n """,characteristic_name
416,n,arms;measures,characteristic_name,n,characteristic_name
417,p value for interaction,arms;measures;p-interaction,measures,p value for interaction,measures
418,macce ( % ) abciximab placebo,arms;measures;p-interaction,arms,macce ( % ) abciximab placebo,arms
419,"macce ( % ) abciximab placebo """,arms;measures;p-interaction,arms,"macce ( % ) abciximab placebo """,arms
420,relative risk ( nmbr % confidence interval ),arms;measures;p-interaction,measures,relative risk ( nmbr % confidence interval ),measures
421,"placebo , n / n ( % ) """,arms;measures,arms,"placebo , n / n ( % ) """,arms
422,"extended - duration enoxaparin , n / n ( % )",arms;measures,arms,"extended - duration enoxaparin , n / n ( % )",arms
423,"absolute risk difference ( ci ) , % *",arms;measures,measures,"absolute risk difference ( ci ) , % *",measures
424,"placebo , n / n ( % )",arms;measures,arms,"placebo , n / n ( % )",arms
425,fp ( n[nmbr ),arms;measures,characteristic_level,fp ( n[nmbr ),characteristic_level
426,sfc ( n[nmbr ),arms;measures,measures,sfc ( n[nmbr ),measures
428,placebo ( n[nmbr ),arms;measures,arms,placebo ( n[nmbr ),arms
429,salmeterol ( n[nmbr ),arms;measures,arms,salmeterol ( n[nmbr ),arms
431,ivabradine group,arms;measures,arms,ivabradine group,arms
432,"ivabradine group """,arms;measures,arms,"ivabradine group """,arms
434,placebo group,arms;measures,arms,placebo group,arms
435,"tertile nmbr ( n = nmbr ) """,characteristic_level;measures,characteristic_level,"tertile nmbr ( n = nmbr ) """,characteristic_level
436,p value for trend across tertiles,characteristic_level;measures,measures,p value for trend across tertiles,measures
437,"all with coenzyme qnmbr ( n = nmbr , nmbr )",characteristic_level;measures,arms,"all with coenzyme qnmbr ( n = nmbr , nmbr )",arms
438,tertile nmbr ( n = nmbr ),characteristic_level;measures,characteristic_level,tertile nmbr ( n = nmbr ),characteristic_level
439,"tertile nmbr """,outcomes;characteristic_level,characteristic_level,"tertile nmbr """,characteristic_level
440,all randomized all - cause mortality,outcomes;characteristic_level,outcomes,all randomized all - cause mortality,outcomes
441,primary end point |,outcomes;characteristic_level,measures,primary end point |,measures
442,tertile nmbr,outcomes;characteristic_level,characteristic_level,tertile nmbr,characteristic_level
443,all randomized,outcomes;characteristic_level,outcomes,all randomized,outcomes
444,all randomized coronary end point,outcomes;characteristic_level,characteristic_name,all randomized coronary end point,characteristic_name
445,all randomized all - cause mortality or hospitalization for worsening hf^,outcomes;characteristic_level,outcomes,all randomized all - cause mortality or hospitalization for worsening hf^,outcomes
448,rolofylline,arms;measures,characteristic_name,rolofylline,characteristic_name
449,"mayo < nmbr , n",measures;characteristic_level,characteristic_level,"mayo < nmbr , n",characteristic_level
450,"no aminosalicylates , n",measures;characteristic_level,characteristic_level,"no aminosalicylates , n",characteristic_level
451,"difference from placebo ( nmbr % ci ) """,measures;characteristic_level,measures,"difference from placebo ( nmbr % ci ) """,measures
452,"crp < nmbr mg / l , n",measures;characteristic_level,arms,"crp < nmbr mg / l , n",arms
453,"remission , n ( % )",measures;characteristic_level,arms,"remission , n ( % )",arms
454,"immy ( without corticosteroid ) , n",measures;characteristic_level,characteristic_level,"immy ( without corticosteroid ) , n",characteristic_level
455,"weight < nmbr . nmbr kg , n",measures;characteristic_level,characteristic_level,"weight < nmbr . nmbr kg , n",characteristic_level
456,"mayo $ nmbr , n",measures;characteristic_level,characteristic_level,"mayo $ nmbr , n",characteristic_level
457,difference from placebo * ( nmbr % ci ),measures;characteristic_level,measures,difference from placebo * ( nmbr % ci ),measures
458,difference from placebo ( nmbr % ci ),measures;characteristic_level,measures,difference from placebo ( nmbr % ci ),measures
459,"weight $ nmbr . nmbr kg , n",measures;characteristic_level,characteristic_level,"weight $ nmbr . nmbr kg , n",characteristic_level
460,"corticosteroid ( without imm ) , n",measures;characteristic_level,characteristic_level,"corticosteroid ( without imm ) , n",characteristic_level
461,"no extensive colitis , n",measures;characteristic_level,characteristic_level,"no extensive colitis , n",characteristic_level
462,"extensive colitis , n",measures;characteristic_level,characteristic_level,"extensive colitis , n",characteristic_level
463,"no corticosteroid + no imm , n",measures;characteristic_level,characteristic_level,"no corticosteroid + no imm , n",characteristic_level
464,"crp $ nmbr mg / l , n",measures;characteristic_level,arms,"crp $ nmbr mg / l , n",arms
465,"weight $ nmbr . nmbr kg , < nmbr . nmbr kg , n",measures;characteristic_level,characteristic_level,"weight $ nmbr . nmbr kg , < nmbr . nmbr kg , n",characteristic_level
466,"imm + corticosteroid , n",measures;characteristic_level,characteristic_level,"imm + corticosteroid , n",characteristic_level
467,"aminosalicylates , n",measures;characteristic_level,arms,"aminosalicylates , n",arms
468,bosentan,arms;measures,characteristic_name,bosentan,characteristic_name
471,nmbr % cl,arms;measures,measures,nmbr % cl,measures
472,"bosentan """,arms;measures,characteristic_name,"bosentan """,characteristic_name
473,"sal ( n = nmbr ) """,arms;measures,characteristic_level,"sal ( n = nmbr ) """,characteristic_level
474,sal ( n = nmbr ),arms;measures,characteristic_level,sal ( n = nmbr ),characteristic_level
476,fp ( n = nmbr ),arms;measures,characteristic_level,fp ( n = nmbr ),characteristic_level
477,sfc ( n = nmbr ),arms;measures,measures,sfc ( n = nmbr ),measures
478,total ho population ( n = nmbr ),arms;measures,other,total ho population ( n = nmbr ),other
479,total population ( n = nmbr ),arms;measures,other,total population ( n = nmbr ),other
480,rr^ ( nmbr % ci ),arms;measures,measures,rr^ ( nmbr % ci ),measures
481,"pla """,arms;measures,arms,"pla """,arms
482,r | r ' ' ' ( nmbr % ci ),arms;measures,measures,r | r ' ' ' ( nmbr % ci ),measures
483,asa,arms;measures,characteristic_level,asa,characteristic_level
485,history of chd,characteristic_level;measures,characteristic_name,history of chd,characteristic_name
486,mean ( sd ),characteristic_level;measures,characteristic_level,mean ( sd ),characteristic_level
487,hypertension *,characteristic_level;measures,characteristic_level,hypertension *,characteristic_level
488,hyperlipidemia^,characteristic_level;measures,arms,hyperlipidemia^,arms
489,history of carotid artery disease,characteristic_level;measures,characteristic_name,history of carotid artery disease,characteristic_name
490,history of peripheral artery disease,characteristic_level;measures,characteristic_name,history of peripheral artery disease,characteristic_name
491,male,characteristic_level;measures,characteristic_level,male,characteristic_level
492,range,characteristic_level;measures,characteristic_level,range,characteristic_level
493,"history of pci """,characteristic_level;measures,characteristic_name,"history of pci """,characteristic_name
494,current smoker,characteristic_level;measures,characteristic_level,current smoker,characteristic_level
495,history of pci,characteristic_level;measures,characteristic_name,history of pci,characteristic_name
496,diabetes mellitus,characteristic_level;measures,characteristic_level,diabetes mellitus,characteristic_level
497,"group c ( n = nmbr ) """,p-interaction;other,arms,"group c ( n = nmbr ) """,arms
498,group b ( n = nmbr ),p-interaction;other,arms,group b ( n = nmbr ),arms
499,p,p-interaction;other,characteristic_name,p,characteristic_name
500,group c ( n = nmbr ),p-interaction;other,arms,group c ( n = nmbr ),arms
501,group a ( n = nmbr ),p-interaction;other,arms,group a ( n = nmbr ),arms
502,"cmh rr ( nmbr % ci ) """,measures;arms,measures,"cmh rr ( nmbr % ci ) """,measures
503,cox hr ( nmbr % ci ),measures;arms,measures,cox hr ( nmbr % ci ),measures
504,"total comparators , patients with events / total patients",measures;arms,measures,"total comparators , patients with events / total patients",measures
505,"linagliptin , patients with events / total patients",measures;arms,measures,"linagliptin , patients with events / total patients",measures
506,cmh rr ( nmbr % ci ),measures;arms,measures,cmh rr ( nmbr % ci ),measures
507,p - value for interaction,arms;measures;p-interaction,measures,p - value for interaction,measures
508,"hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr )",arms;measures;p-interaction,measures,"hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr )",measures
509,vorapaxar placebo nmbr - yr %,arms;measures;p-interaction,arms,vorapaxar placebo nmbr - yr %,arms
510,"hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr ) """,arms;measures;p-interaction,measures,"hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr ) """,measures
511,p - value for interaction,arms;p-interaction,measures,p - value for interaction,measures
512,"p - value for interaction """,arms;p-interaction,measures,"p - value for interaction """,measures
513,nonmetabolic syndrome ( n = nmbr ),characteristic_level;measures,characteristic_level,nonmetabolic syndrome ( n = nmbr ),characteristic_level
514,"nonmetabolic syndrome ( n = nmbr ) """,characteristic_level;measures,characteristic_level,"nonmetabolic syndrome ( n = nmbr ) """,characteristic_level
515,metabolic syndrome ( n = nmbr ),characteristic_level;measures,characteristic_level,metabolic syndrome ( n = nmbr ),characteristic_level
516,p value,characteristic_level;measures,measures,p value,measures
517,"patients without ra , as , or psa ( n = nmbr , nmbr )",arms;measures,characteristic_level,"patients without ra , as , or psa ( n = nmbr , nmbr )",characteristic_level
518,"patients with ra , as , or psa ( n = nmbr )",arms;measures,characteristic_level,"patients with ra , as , or psa ( n = nmbr )",characteristic_level
520,"patients without ra , as , or psa ( n = nmbr , nmbr ) """,arms;measures,characteristic_level,"patients without ra , as , or psa ( n = nmbr , nmbr ) """,characteristic_level
521,"atorvastatin nmbr mg ( n = nmbr , nmbr )",arms;measures,arms,"atorvastatin nmbr mg ( n = nmbr , nmbr )",arms
522,simvastatin nmbr mg ( n = nmbr ),arms;measures,arms,simvastatin nmbr mg ( n = nmbr ),arms
523,"pt """,arms;measures,measures,"pt """,measures
524,p +,arms;measures,characteristic_name,p +,characteristic_name
526,"simvastatin nmbr mg ( n = nmbr , nmbr )",arms;measures,arms,"simvastatin nmbr mg ( n = nmbr , nmbr )",arms
527,atorvastatin nmbr mg ( n = nmbr ),arms;measures,arms,atorvastatin nmbr mg ( n = nmbr ),arms
528,standard care n ( % ) / nmbrpy,measures;arms,arms,standard care n ( % ) / nmbrpy,arms
529,hr ( nmbr % cl ),measures;arms,measures,hr ( nmbr % cl ),measures
530,"hr ( nmbr % cl ) """,measures;arms,measures,"hr ( nmbr % cl ) """,measures
531,p,measures;arms,characteristic_name,p,characteristic_name
532,insulin glargine n ( % ) / nmbrpy,measures;arms,arms,insulin glargine n ( % ) / nmbrpy,arms
533,"egfr , ml / min / nmbr . nmbr mnmbr , mean ( sd )",characteristic_level;measures,characteristic_level,"egfr , ml / min / nmbr . nmbr mnmbr , mean ( sd )",characteristic_level
534,prediabeticb,characteristic_level;measures,characteristic_name,prediabeticb,characteristic_name
536,median,characteristic_level;measures,characteristic_level,median,characteristic_level
537,"age , y , mean ( sd )",characteristic_level;measures,characteristic_name,"age , y , mean ( sd )",characteristic_name
538,"> nmbr y , no . ( % )",characteristic_level;measures,characteristic_level,"> nmbr y , no . ( % )",characteristic_level
539,"normoglycemicnmbr """,characteristic_level;measures,characteristic_name,"normoglycemicnmbr """,characteristic_name
540,diabeticnmbr,characteristic_level;measures,characteristic_name,diabeticnmbr,characteristic_name
541,"hbanmbrc , % , mean ( sd )",characteristic_level;measures,characteristic_name,"hbanmbrc , % , mean ( sd )",characteristic_name
542,normoglycemicnmbr,characteristic_level;measures,characteristic_name,normoglycemicnmbr,characteristic_name
548,vorapaxar placebo nmbr - yr . km %,arms;measures,arms,vorapaxar placebo nmbr - yr . km %,arms
549,hr ( nmbr % ci ) p value for interaction *,arms;measures,measures,hr ( nmbr % ci ) p value for interaction *,measures
550,"vorapaxar placebo nmbr - yr . km % """,arms;measures,arms,"vorapaxar placebo nmbr - yr . km % """,arms
551,"ics use , yes / no %",characteristic_name;characteristic_level,characteristic_level,"ics use , yes / no %",characteristic_level
552,"sex , male / female , %",characteristic_name;characteristic_level,characteristic_level,"sex , male / female , %",characteristic_level
553,fevnmbr / fvc ( post - albuterol ),characteristic_name;characteristic_level,characteristic_name,fevnmbr / fvc ( post - albuterol ),characteristic_name
554,"smoking history , pack - years",characteristic_name;characteristic_level,characteristic_name,"smoking history , pack - years",characteristic_name
555,"age , years """,characteristic_name;characteristic_level,characteristic_name,"age , years """,characteristic_name
556,baseline dyspnea index score,characteristic_name;characteristic_level,characteristic_name,baseline dyspnea index score,characteristic_name
557,"race , % caucasian",characteristic_name;characteristic_level,characteristic_name,"race , % caucasian",characteristic_name
558,"age , years",characteristic_name;characteristic_level,characteristic_name,"age , years",characteristic_name
559,severe / very severea,characteristic_name;characteristic_level,characteristic_level,severe / very severea,characteristic_level
560,baseline sgrq score,characteristic_name;characteristic_level,characteristic_name,baseline sgrq score,characteristic_name
561,"fevnmbr reversibility , % b",characteristic_name;characteristic_level,characteristic_name,"fevnmbr reversibility , % b",characteristic_name
562,"ex - smoker / smoker , %",characteristic_name;characteristic_level,characteristic_name,"ex - smoker / smoker , %",characteristic_name
563,asian,characteristic_name;characteristic_level,characteristic_level,asian,characteristic_level
564,"fevnmbr ( post - albuterol ) , l",characteristic_name;characteristic_level,characteristic_name,"fevnmbr ( post - albuterol ) , l",characteristic_name
565,black,characteristic_name;characteristic_level,characteristic_level,black,characteristic_level
566,"duration of copd , years",characteristic_name;characteristic_level,characteristic_name,"duration of copd , years",characteristic_name
567,"fevnmbr ( pre - albuterol ) , l",characteristic_name;characteristic_level,characteristic_name,"fevnmbr ( pre - albuterol ) , l",characteristic_name
569,"severity of copd , n ( % ) ( gold nmbr ) : moderate",characteristic_name;characteristic_level,characteristic_name,"severity of copd , n ( % ) ( gold nmbr ) : moderate",characteristic_name
570,"fevnmbr % pred . ( post - albuterol ) , %",characteristic_name;characteristic_level,characteristic_name,"fevnmbr % pred . ( post - albuterol ) , %",characteristic_name
571,( baseline ),outcomes;measures,characteristic_name,( baseline ),characteristic_name
572,sgrq total score,outcomes;measures,arms,sgrq total score,arms
573,sgrq total score ( week,outcomes;measures,outcomes,sgrq total score ( week,outcomes
574,"sgrq total score ( week """,outcomes;measures,outcomes,"sgrq total score ( week """,outcomes
575,nmbr locf ),outcomes;measures,characteristic_level,nmbr locf ),characteristic_level
576,change from baseline,outcomes;measures,measures,change from baseline,measures
577,bdi total score ( baseline ),outcomes;measures,characteristic_name,bdi total score ( baseline ),characteristic_name
578,locf ),outcomes;measures,characteristic_name,locf ),characteristic_name
579,tdi total score ( week nmbr,outcomes;measures,other,tdi total score ( week nmbr,other
580,"fevnmbr , % predicteda",characteristic_name;characteristic_level,characteristic_name,"fevnmbr , % predicteda",characteristic_name
581,indian,characteristic_name;characteristic_level,characteristic_level,indian,characteristic_level
582,"ics use , %",characteristic_name;characteristic_level,characteristic_name,"ics use , %",characteristic_name
585,"fevnmbr / fvc , % a",characteristic_name;characteristic_level,characteristic_name,"fevnmbr / fvc , % a",characteristic_name
586,"smoking history , """,characteristic_name;characteristic_level,characteristic_name,"smoking history , """,characteristic_name
587,korean,characteristic_name;characteristic_level,arms,korean,arms
588,japanese,characteristic_name;characteristic_level,characteristic_name,japanese,characteristic_name
589,"fevnmbr , la",characteristic_name;characteristic_level,characteristic_name,"fevnmbr , la",characteristic_name
590,ex - smoker / current,characteristic_name;characteristic_level,characteristic_level,ex - smoker / current,characteristic_level
591,"smoking history ,",characteristic_name;characteristic_level,characteristic_name,"smoking history ,",characteristic_name
592,reversibility to,characteristic_name;characteristic_level,characteristic_name,reversibility to,characteristic_name
593,taiwan,characteristic_name;characteristic_level,characteristic_name,taiwan,characteristic_name
594,"copd severity , n ( % )",characteristic_name;characteristic_level,characteristic_name,"copd severity , n ( % )",characteristic_name
595,"duration of copd ,",characteristic_name;characteristic_level,characteristic_name,"duration of copd ,",characteristic_name
596,"male / female , %",characteristic_name;characteristic_level,characteristic_level,"male / female , %",characteristic_level
597,m o nito ring treatment,arms;p-interaction;other,characteristic_name,m o nito ring treatment,characteristic_name
598,p interaction,arms;p-interaction;other,characteristic_name,p interaction,characteristic_name
599,r elative risk ( nmbr % ci ),arms;p-interaction;other,measures,r elative risk ( nmbr % ci ),measures
600,"conventional treatment """,arms;p-interaction;other,characteristic_name,"conventional treatment """,characteristic_name
601,conventional treatment,arms;p-interaction;other,characteristic_name,conventional treatment,characteristic_name
602,m o nito ring treatment,arms;other;p-interaction,characteristic_name,m o nito ring treatment,characteristic_name
603,p interaction,arms;other;p-interaction,characteristic_name,p interaction,characteristic_name
604,r elative risk ( nmbr % ci ),arms;other;p-interaction,measures,r elative risk ( nmbr % ci ),measures
605,conventional treatment,arms;other;p-interaction,characteristic_name,conventional treatment,characteristic_name
606,"r elative risk ( nmbr % ci ) """,arms;other;p-interaction,measures,"r elative risk ( nmbr % ci ) """,measures
607,ejection fraction : < nmbr % ( n = nmbr ),characteristic_name;characteristic_level,characteristic_name,ejection fraction : < nmbr % ( n = nmbr ),characteristic_name
608,peri - op amiodarone : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,peri - op amiodarone : no ( n = nmbr ),characteristic_level
609,sex : male ( n = nmbr ),characteristic_name;characteristic_level,characteristic_name,sex : male ( n = nmbr ),characteristic_name
610,peri - op beta - blockers : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,peri - op beta - blockers : no ( n = nmbr ),characteristic_level
611,country : argentina ( n = nmbr ),characteristic_name;characteristic_level,characteristic_name,country : argentina ( n = nmbr ),characteristic_name
612,phospholipid omega - nmbr levels : < nmbr % ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,phospholipid omega - nmbr levels : < nmbr % ( n = nmbr ),characteristic_level
613,"peri - op beta - blockers : no ( n = nmbr ) """,characteristic_name;characteristic_level,characteristic_level,"peri - op beta - blockers : no ( n = nmbr ) """,characteristic_level
614,peri - op statins : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,peri - op statins : no ( n = nmbr ),characteristic_level
615,left atrial diameter : < nmbr mm ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,left atrial diameter : < nmbr mm ( n = nmbr ),characteristic_level
616,hypertension : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,hypertension : no ( n = nmbr ),characteristic_level
617,overall ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,overall ( n = nmbr ),characteristic_level
618,age : < nmbr years ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,age : < nmbr years ( n = nmbr ),characteristic_level
619,cardiac valve surgery : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,cardiac valve surgery : no ( n = nmbr ),characteristic_level
620,nyha class nmbr - nmbr : no { n = llll ),characteristic_name;characteristic_level,characteristic_level,nyha class nmbr - nmbr : no { n = llll ),characteristic_level
621,study drug loading days ( actual ) : nmbr ( n = nmbr ),characteristic_name;characteristic_level,other,study drug loading days ( actual ) : nmbr ( n = nmbr ),other
622,peri - op ace - inhibitors / arbs : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,peri - op ace - inhibitors / arbs : no ( n = nmbr ),characteristic_level
623,habitual fish intake : < nmbr servings / wk ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,habitual fish intake : < nmbr servings / wk ( n = nmbr ),characteristic_level
624,serum potassium : < nmbr . nmbrmmol / l ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,serum potassium : < nmbr . nmbrmmol / l ( n = nmbr ),characteristic_level
625,cross - damp time : < l : llhrs : min ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,cross - damp time : < l : llhrs : min ( n = nmbr ),characteristic_level
626,on - pump time : < l : nmbrhrs : min ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level,on - pump time : < l : nmbrhrs : min ( n = nmbr ),characteristic_level
628,( nmbr % cl ) interaction,arms;p-interaction,measures,( nmbr % cl ) interaction,measures
629,n - nmbr pufa,arms;p-interaction,arms,n - nmbr pufa,arms
631,"baseline crp < nmbrmg / l """,characteristic_name;measures,characteristic_name,"baseline crp < nmbrmg / l """,characteristic_name
632,% change median baseline crp > nmbrmg / l,characteristic_name;measures,measures,% change median baseline crp > nmbrmg / l,measures
633,baseline crp < nmbrmg / l,characteristic_name;measures,characteristic_name,baseline crp < nmbrmg / l,characteristic_name
634,baseline,other;measures,characteristic_name,baseline,characteristic_name
635,"baseline """,other;measures,characteristic_name,"baseline """,characteristic_name
636,week nmbr,other;measures,measures,week nmbr,measures
637,change from baseline,other;measures,measures,change from baseline,measures
638,fibrinolysis ( n = nmbr ),arms;other,characteristic_level,fibrinolysis ( n = nmbr ),characteristic_level
639,primary pci ( n = nmbr ),arms;other,outcomes,primary pci ( n = nmbr ),outcomes
640,"p valuey """,arms;other,characteristic_name,"p valuey """,characteristic_name
641,p valuey,arms;other,characteristic_name,p valuey,characteristic_name
642,fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ),arms;measures;other;p-interaction,characteristic_level,fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ),characteristic_level
643,"fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ) """,arms;measures;other;p-interaction,characteristic_level,"fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ) """,characteristic_level
644,p value for interaction,arms;measures;other;p-interaction,measures,p value for interaction,measures
645,relative risk ( nmbr % ci ) ofprimary end point,arms;measures;other;p-interaction,measures,relative risk ( nmbr % ci ) ofprimary end point,measures
646,p value,arms;measures;other;p-interaction,measures,p value,measures
647,control ( n = nmbr ),arms;other,arms,control ( n = nmbr ),arms
648,watchman ( n = nmbr ),arms;other,characteristic_level,watchman ( n = nmbr ),characteristic_level
649,"p value """,arms;other,measures,"p value """,measures
650,p value,arms;other,measures,p value,measures
651,all,characteristic_name;measures,outcomes,all,outcomes
652,diabetes,characteristic_name;measures,characteristic_level,diabetes,characteristic_level
653,p,characteristic_name;measures,characteristic_name,p,characteristic_name
654,"p """,characteristic_name;measures,characteristic_name,"p """,characteristic_name
655,no diabetes,characteristic_name;measures,characteristic_level,no diabetes,characteristic_level
656,p value *,arms;measures,measures,p value *,measures
657,control ( n - nmbr ),arms;measures,arms,control ( n - nmbr ),arms
658,"control ( n - nmbr ) """,arms;measures,arms,"control ( n - nmbr ) """,arms
659,statin ( n - nmbr ),arms;measures,arms,statin ( n - nmbr ),arms
660,oradj ( nmbr % cl ),arms;measures;p-interaction,measures,oradj ( nmbr % cl ),measures
661,"events / control group """,arms;measures;p-interaction,arms,"events / control group """,arms
662,p for interaction,arms;measures;p-interaction,characteristic_name,p for interaction,characteristic_name
663,events / control group,arms;measures;p-interaction,arms,events / control group,arms
664,events / statin group,arms;measures;p-interaction,measures,events / statin group,measures
665,orc ( nmbr % cl ),arms;measures;p-interaction,measures,orc ( nmbr % cl ),measures
666,p value,arms;measures;p-interaction,measures,p value,measures
667,p [int],arms;measures;p-interaction,characteristic_name,p [int],characteristic_name
668,ipst,arms;measures;p-interaction,characteristic_name,ipst,characteristic_name
669,"ipst """,arms;measures;p-interaction,characteristic_name,"ipst """,characteristic_name
670,no ipst,arms;measures;p-interaction,measures,no ipst,measures
671,or [nmbr % ci],arms;measures;p-interaction,other,or [nmbr % ci],other
672,"ff nmbr gg ( n = nmbr , nmbr ) """,arms;measures,arms,"ff nmbr gg ( n = nmbr , nmbr ) """,arms
673,"ff nmbr gg ( n = nmbr , nmbr )",arms;measures,arms,"ff nmbr gg ( n = nmbr , nmbr )",arms
674,"total ( n = nmbr , nmbr )",arms;measures,arms,"total ( n = nmbr , nmbr )",arms
675,"ff / vi nmbr / nmbr gg ( n = nmbr , nmbr )",arms;measures,arms,"ff / vi nmbr / nmbr gg ( n = nmbr , nmbr )",arms
676,indacaterol nmbr ug ( n = nmbr ),arms;measures,arms,indacaterol nmbr ug ( n = nmbr ),arms
677,"total ( n = nmbr ) """,arms;measures,arms,"total ( n = nmbr ) """,arms
678,total ( n = nmbr ),arms;measures,arms,total ( n = nmbr ),arms
680,overall,characteristic_name;characteristic_level,characteristic_level,overall,characteristic_level
681,sex : male,characteristic_name;characteristic_level,characteristic_name,sex : male,characteristic_name
682,bmi : < nmbr . nmbr kg / mnmbr,characteristic_name;characteristic_level,characteristic_level,bmi : < nmbr . nmbr kg / mnmbr,characteristic_level
683,smoking : current smoker,characteristic_name;characteristic_level,characteristic_level,smoking : current smoker,characteristic_level
684,ics use at baseline : yes,characteristic_name;characteristic_level,characteristic_name,ics use at baseline : yes,characteristic_name
685,reversibility : > nmbr %,characteristic_name;characteristic_level,characteristic_level,reversibility : > nmbr %,characteristic_level
686,bmi : > nmbr . nmbr kg / mnmbr,characteristic_name;characteristic_level,characteristic_level,bmi : > nmbr . nmbr kg / mnmbr,characteristic_level
687,reversibility : < nmbr %,characteristic_name;characteristic_level,characteristic_level,reversibility : < nmbr %,characteristic_level
688,"sex : male """,characteristic_name;characteristic_level,characteristic_name,"sex : male """,characteristic_name
689,age : < nmbr years,characteristic_name;characteristic_level,characteristic_level,age : < nmbr years,characteristic_level
690,smoking : ex - smoker,characteristic_name;characteristic_level,characteristic_name,smoking : ex - smoker,characteristic_name
691,sex : female,characteristic_name;characteristic_level,characteristic_name,sex : female,characteristic_name
692,severe or worse airflow limitation,characteristic_name;characteristic_level,characteristic_level,severe or worse airflow limitation,characteristic_level
693,age : > nmbr years,characteristic_name;characteristic_level,characteristic_level,age : > nmbr years,characteristic_level
694,reversibility : > nmbr - < nmbr %,characteristic_name;characteristic_level,characteristic_level,reversibility : > nmbr - < nmbr %,characteristic_level
695,ics use at baseline : no,characteristic_name;characteristic_level,characteristic_name,ics use at baseline : no,characteristic_name
696,moderate or less airflow limitation,characteristic_name;characteristic_level,characteristic_level,moderate or less airflow limitation,characteristic_level
697,age < nmbryrs,characteristic_level;characteristic_name,characteristic_name,age < nmbryrs,characteristic_name
698,bl updrs : low,characteristic_level;characteristic_name,characteristic_name,bl updrs : low,characteristic_name
699,bl h / y : unilateral,characteristic_level;characteristic_name,characteristic_name,bl h / y : unilateral,characteristic_name
700,age nmbr + yrs,characteristic_level;characteristic_name,characteristic_level,age nmbr + yrs,characteristic_level
701,male,characteristic_level;characteristic_name,characteristic_level,male,characteristic_level
702,female,characteristic_level;characteristic_name,characteristic_level,female,characteristic_level
703,bl updrs : high,characteristic_level;characteristic_name,characteristic_level,bl updrs : high,characteristic_level
704,bl h / y : bilateral,characteristic_level;characteristic_name,characteristic_name,bl h / y : bilateral,characteristic_name
705,"bl updrs : low """,characteristic_level;characteristic_name,characteristic_name,"bl updrs : low """,characteristic_name
706,p - value ( lnteraction ),measures;p-interaction,measures,p - value ( lnteraction ),measures
707,"nmbrmg vs placebo """,measures;p-interaction,arms,"nmbrmg vs placebo """,arms
708,nmbrmg vs placebo,measures;p-interaction,arms,nmbrmg vs placebo,arms
709,men,characteristic_name;characteristic_level,characteristic_level,men,characteristic_level
710,hba < median,characteristic_name;characteristic_level,characteristic_level,hba < median,characteristic_level
711,"education > nmbr years """,characteristic_name;characteristic_level,characteristic_level,"education > nmbr years """,characteristic_level
712,omega - nmbr fatty acid,characteristic_name;characteristic_level,arms,omega - nmbr fatty acid,arms
714,age < nmbr years,characteristic_name;characteristic_level,characteristic_level,age < nmbr years,characteristic_level
715,depression,characteristic_name;characteristic_level,characteristic_name,depression,characteristic_name
716,women,characteristic_name;characteristic_level,characteristic_level,women,characteristic_level
717,placebo,characteristic_name;characteristic_level,arms,placebo,arms
718,education < nmbr years,characteristic_name;characteristic_level,characteristic_level,education < nmbr years,characteristic_level
719,hbak < median,characteristic_name;characteristic_level,characteristic_level,hbak < median,characteristic_level
720,hbak > median,characteristic_name;characteristic_level,characteristic_level,hbak > median,characteristic_level
721,no depression,characteristic_name;characteristic_level,measures,no depression,measures
722,diabetes,characteristic_name;characteristic_level,characteristic_level,diabetes,characteristic_level
723,no diabetes,characteristic_name;characteristic_level,characteristic_level,no diabetes,characteristic_level
724,education > nmbr years,characteristic_name;characteristic_level,characteristic_level,education > nmbr years,characteristic_level
725,age > nmbr years,characteristic_name;characteristic_level,characteristic_level,age > nmbr years,characteristic_level
726,hbalc > median,characteristic_name;characteristic_level,characteristic_level,hbalc > median,characteristic_level
727,education nmbr - nmbr years,characteristic_name;characteristic_level,characteristic_level,education nmbr - nmbr years,characteristic_level
728,number standard care,p-interaction;measures,arms,number standard care,arms
729,number insulin glargine,p-interaction;measures,arms,number insulin glargine,arms
730,p nmbr interaction,p-interaction;measures,characteristic_name,p nmbr interaction,characteristic_name
731,insulin glargine vs standard care least - squares mean ( nmbr % cl ),p-interaction;measures,arms,insulin glargine vs standard care least - squares mean ( nmbr % cl ),arms
732,"number standard care """,p-interaction;measures,arms,"number standard care """,arms
741,insulin glargine,characteristic_name;characteristic_level,arms,insulin glargine,arms
744,standard care,characteristic_name;characteristic_level,arms,standard care,arms
746,hbalc < median,characteristic_name;characteristic_level,characteristic_level,hbalc < median,characteristic_level
750,number omega - nmbr number placeb fatty acid,measures;p-interaction,characteristic_name,number omega - nmbr number placeb fatty acid,characteristic_name
751,omega - nmbr fatty acid vs placebo least - squares mean ( nmbr % cl ),measures;p-interaction,arms,omega - nmbr fatty acid vs placebo least - squares mean ( nmbr % cl ),arms
752,p . interaction,measures;p-interaction,characteristic_name,p . interaction,characteristic_name
753,"number omega - nmbr number placeb fatty acid """,measures;p-interaction,characteristic_name,"number omega - nmbr number placeb fatty acid """,characteristic_name
754,bmi < nmbrkg / mnmbr,characteristic_name;characteristic_level,characteristic_level,bmi < nmbrkg / mnmbr,characteristic_level
755,with beta blocker,characteristic_name;characteristic_level,characteristic_level,with beta blocker,characteristic_level
756,family history of diabetes ( - ),characteristic_name;characteristic_level,characteristic_name,family history of diabetes ( - ),characteristic_name
757,without acei / arb,characteristic_name;characteristic_level,characteristic_level,without acei / arb,characteristic_level
758,age > = nmbr years old,characteristic_name;characteristic_level,characteristic_level,age > = nmbr years old,characteristic_level
759,age < nmbr years old,characteristic_name;characteristic_level,characteristic_level,age < nmbr years old,characteristic_level
760,fbs < nmbr mg / dl,characteristic_name;characteristic_level,characteristic_level,fbs < nmbr mg / dl,characteristic_level
762,male,characteristic_name;characteristic_level,characteristic_level,male,characteristic_level
763,with acei / arb,characteristic_name;characteristic_level,arms,with acei / arb,arms
764,without beta blocker,characteristic_name;characteristic_level,characteristic_level,without beta blocker,characteristic_level
765,"age > = nmbr years old """,characteristic_name;characteristic_level,characteristic_level,"age > = nmbr years old """,characteristic_level
766,family history of diabetes ( + ),characteristic_name;characteristic_level,characteristic_name,family history of diabetes ( + ),characteristic_name
767,all patients,characteristic_name;characteristic_level,characteristic_level,all patients,characteristic_level
768,bmi > = nmbrkg / mnmbr,characteristic_name;characteristic_level,characteristic_level,bmi > = nmbrkg / mnmbr,characteristic_level
769,fbs > = nmbr mg / dl,characteristic_name;characteristic_level,characteristic_level,fbs > = nmbr mg / dl,characteristic_level
770,unadjusted hr,measures;p-interaction,measures,unadjusted hr,measures
771,"number ( % ) """,measures;p-interaction,characteristic_name,"number ( % ) """,characteristic_name
772,p : interaction,measures;p-interaction,characteristic_name,p : interaction,characteristic_name
773,number ( % ),measures;p-interaction,characteristic_name,number ( % ),characteristic_name
774,relative risk ( nmbr % cl ),arms;measures;p-interaction,measures,relative risk ( nmbr % cl ),measures
775,interruption,arms;measures;p-interaction,characteristic_name,interruption,characteristic_name
777,"relative risk ( nmbr % cl ) """,arms;measures;p-interaction,measures,"relative risk ( nmbr % cl ) """,measures
778,continuation,arms;measures;p-interaction,characteristic_name,continuation,characteristic_name
779,"interruption """,arms;measures;p-interaction,characteristic_name,"interruption """,characteristic_name
784,p - value ( int ),measures;p-interaction,measures,p - value ( int ),measures
785,"endpoint rate """,measures;p-interaction,measures,"endpoint rate """,measures
786,endpoint rate,measures;p-interaction,measures,endpoint rate,measures
787,interact !,measures;arms;p-interaction,characteristic_name,interact !,characteristic_name
788,"hazard ratio ( nmbr % cl ) """,measures;arms;p-interaction,measures,"hazard ratio ( nmbr % cl ) """,measures
789,hazard ratio ( nmbr % cl ),measures;arms;p-interaction,measures,hazard ratio ( nmbr % cl ),measures
791,sal nmbr pg ( n = nmbr ),arms;measures,arms,sal nmbr pg ( n = nmbr ),arms
792,fp / sal nmbr / nmbr pg ( n = nmbr ),arms;measures,arms,fp / sal nmbr / nmbr pg ( n = nmbr ),arms
793,"sal nmbr pg ( n = nmbr ) """,arms;measures,arms,"sal nmbr pg ( n = nmbr ) """,arms
794,dapa + met n = nmbr,arms;measures,arms,dapa + met n = nmbr,arms
795,"total n = nmbr """,arms;measures,arms,"total n = nmbr """,arms
796,saxa + dapa + met n = nmbr,arms;measures,arms,saxa + dapa + met n = nmbr,arms
797,saxa + met n = nmbr,arms;measures,arms,saxa + met n = nmbr,arms
798,total n = nmbr,arms;measures,arms,total n = nmbr,arms
799,device group,arms;other,arms,device group,arms
800,"device group """,arms;other,arms,"device group """,arms
801,hr ( nmbr % ci ),arms;other,measures,hr ( nmbr % ci ),measures
802,warfarin group,arms;other,arms,warfarin group,arms
803,n,measures;arms;p-interaction;other,characteristic_name,n,characteristic_name
804,hrnmbr and nmbr % cl,measures;arms;p-interaction;other,measures,hrnmbr and nmbr % cl,measures
805,continued thienopyridine n ( % ),measures;arms;p-interaction;other,arms,continued thienopyridine n ( % ),arms
806,p value for interaction,measures;arms;p-interaction;other,measures,p value for interaction,measures
807,placebo n ( % ),measures;arms;p-interaction;other,arms,placebo n ( % ),arms
808,"continued thienopyridine n ( % ) """,measures;arms;p-interaction;other,arms,"continued thienopyridine n ( % ) """,arms
809,"placebo ( n = nmbr , nmbr )",arms;p-interaction,arms,"placebo ( n = nmbr , nmbr )",arms
810,"placebo ( n = nmbr , nmbr ) """,arms;p-interaction,arms,"placebo ( n = nmbr , nmbr ) """,arms
811,"vorapaxar ( n = nmbr , nmbr )",arms;p-interaction,arms,"vorapaxar ( n = nmbr , nmbr )",arms
813,women > nmbr years,characteristic_name;characteristic_level,characteristic_level,women > nmbr years,characteristic_level
814,total study population,characteristic_name;characteristic_level,other,total study population,other
815,women < nmbr years,characteristic_name;characteristic_level,characteristic_level,women < nmbr years,characteristic_level
816,"total study population """,characteristic_name;characteristic_level,other,"total study population """,other
817,hr ( nmbr % ci ),arms;measures;p-interaction,measures,hr ( nmbr % ci ),measures
818,"saxagliptin nmbr mg ( n = nmbr , nmbr )",arms;measures;p-interaction,arms,"saxagliptin nmbr mg ( n = nmbr , nmbr )",arms
819,saxagliptin nmbr . nmbr mg ( n = nmbr ),arms;measures;p-interaction,arms,saxagliptin nmbr . nmbr mg ( n = nmbr ),arms
820,"hr ( nmbr % ci ) """,arms;measures;p-interaction,measures,"hr ( nmbr % ci ) """,measures
821,"saxagliptin nmbr . nmbr mg ( n = nmbr , nmbr )",arms;measures;p-interaction,arms,"saxagliptin nmbr . nmbr mg ( n = nmbr , nmbr )",arms
822,placebo ( n = nmbr ),arms;measures;p-interaction,arms,placebo ( n = nmbr ),arms
823,"placebo ( n = nmbr , nmbr )",arms;measures;p-interaction,arms,"placebo ( n = nmbr , nmbr )",arms
824,p,arms;measures;p-interaction,characteristic_name,p,characteristic_name
825,p for interaction *,arms;measures;p-interaction,characteristic_name,p for interaction *,characteristic_name
826,"hr ( nmbr % cl ) """,measures;p-interaction,measures,"hr ( nmbr % cl ) """,measures
827,p - value for interaction,measures;p-interaction,measures,p - value for interaction,measures
828,hr ( nmbr % cl ),measures;p-interaction,measures,hr ( nmbr % cl ),measures
829,nmbr yr km % ( n ),measures;p-interaction,characteristic_level,nmbr yr km % ( n ),characteristic_level
830,no dm ( n = nmbr ),characteristic_level;measures,characteristic_name,no dm ( n = nmbr ),characteristic_name
831,dm ( n = nmbr ),characteristic_level;measures,characteristic_name,dm ( n = nmbr ),characteristic_name
832,"no dm ( n = nmbr ) """,characteristic_level;measures,characteristic_name,"no dm ( n = nmbr ) """,characteristic_name
834,hr ( nmbr % ci ),measures;p-interaction;arms,measures,hr ( nmbr % ci ),measures
835,"vorapaxar event rate ( n = nmbr ) , %",measures;p-interaction;arms,measures,"vorapaxar event rate ( n = nmbr ) , %",measures
836,"placebo event rate ( n = nmbr ) , %",measures;p-interaction;arms,measures,"placebo event rate ( n = nmbr ) , %",measures
837,"vorapaxar event rate ( n = nmbr ) , % """,measures;p-interaction;arms,measures,"vorapaxar event rate ( n = nmbr ) , % """,measures
838,p value ( int ),measures;p-interaction;arms,measures,p value ( int ),measures
839,p value,measures;p-interaction;arms,measures,p value,measures
840,hr,measures;p-interaction,measures,hr,measures
842,nmbr % cl,measures;p-interaction,measures,nmbr % cl,measures
843,"hr """,measures;p-interaction,measures,"hr """,measures
847,nmbr % ci,measures;p-interaction,measures,nmbr % ci,measures
848,saxagliptin,arms;measures,arms,saxagliptin,arms
849,"saxagliptin """,arms;measures,arms,"saxagliptin """,arms
851,vorapaxar placebo nmbr - yr . km % rate,arms;measures;p-interaction,arms,vorapaxar placebo nmbr - yr . km % rate,arms
855,total no .,arms;measures;p-interaction,measures,total no .,measures
857,p vs placebo,arms;measures,arms,p vs placebo,arms
859,nnmbr / nnmbr,measures;arms,characteristic_name,nnmbr / nnmbr,characteristic_name
860,"nnmbr / nnmbr """,measures;arms,characteristic_name,"nnmbr / nnmbr """,characteristic_name
861,lsm ( nmbr % cl ),measures;arms,measures,lsm ( nmbr % cl ),measures
862,"estimated difference """,arms;measures,measures,"estimated difference """,measures
863,estimated difference,arms;measures,measures,estimated difference,measures
864,placebo mean ( n ),arms;measures,arms,placebo mean ( n ),arms
865,liraglutide nmbr . nmbr mg mean ( n ),arms;measures,arms,liraglutide nmbr . nmbr mg mean ( n ),arms
866,p for i,arms;measures,characteristic_name,p for i,characteristic_name
868,"p for i """,arms;measures,characteristic_name,"p for i """,characteristic_name
869,warfarin,arms;measures,arms,warfarin,arms
870,hr nmbr % cl,arms;measures,measures,hr nmbr % cl,measures
871,apixaban,arms;measures,arms,apixaban,arms
872,apixaban vs . placebo,arms;measures,arms,apixaban vs . placebo,arms
875,odds ratio ( nmbr % cl ),arms;measures;p-interaction,measures,odds ratio ( nmbr % cl ),measures
876,cyclo,arms;measures;p-interaction,characteristic_name,cyclo,characteristic_name
877,"p - value for interaction nmbr . nmbr """,arms;measures;p-interaction,measures,"p - value for interaction nmbr . nmbr """,measures
878,control,arms;measures;p-interaction,arms,control,arms
879,p - value for interaction nmbr . nmbr,arms;measures;p-interaction,measures,p - value for interaction nmbr . nmbr,measures
880,no thienopyridine,characteristic_level;p-interaction,arms,no thienopyridine,arms
881,thienopyridine,characteristic_level;p-interaction,arms,thienopyridine,arms
882,"no thienopyridine """,characteristic_level;p-interaction,arms,"no thienopyridine """,arms
883,tp vs no tp,characteristic_level;p-interaction,measures,tp vs no tp,measures
884,vorapaxar n = nmbr,measures;arms,arms,vorapaxar n = nmbr,arms
885,all n = nmbr,measures;arms,characteristic_level,all n = nmbr,characteristic_level
886,all n = nmbr nmbr,measures;arms,characteristic_level,all n = nmbr nmbr,characteristic_level
887,"vorapaxar n = nmbr """,measures;arms,arms,"vorapaxar n = nmbr """,arms
888,placebo n = nmbr,measures;arms,arms,placebo n = nmbr,arms
889,"sex , male",characteristic_level;characteristic_name,characteristic_name,"sex , male",characteristic_name
890,"region , asia / paafic",characteristic_level;characteristic_name,characteristic_name,"region , asia / paafic",characteristic_name
891,age > = nmbr,characteristic_level;characteristic_name,characteristic_name,age > = nmbr,characteristic_name
892,"renal function , normal - mild",characteristic_level;characteristic_name,characteristic_name,"renal function , normal - mild",characteristic_name
893,"renal function , severe",characteristic_level;characteristic_name,characteristic_name,"renal function , severe",characteristic_name
894,"region , europe union",characteristic_level;characteristic_name,characteristic_name,"region , europe union",characteristic_name
895,cvd subjects,characteristic_level;characteristic_name,arms,cvd subjects,arms
896,mrf subjects,characteristic_level;characteristic_name,arms,mrf subjects,arms
897,age < nmbr,characteristic_level;characteristic_name,characteristic_name,age < nmbr,characteristic_name
898,"region , europe",characteristic_level;characteristic_name,characteristic_name,"region , europe",characteristic_name
899,"sex , female",characteristic_level;characteristic_name,characteristic_name,"sex , female",characteristic_name
900,"race , while",characteristic_level;characteristic_name,characteristic_name,"race , while",characteristic_name
901,"region , latin america",characteristic_level;characteristic_name,characteristic_name,"region , latin america",characteristic_name
902,"region , north america",characteristic_level;characteristic_name,characteristic_name,"region , north america",characteristic_name
903,"renal function , moderate",characteristic_level;characteristic_name,characteristic_name,"renal function , moderate",characteristic_name
904,oretal,characteristic_level;characteristic_name,characteristic_name,oretal,characteristic_name
905,"renal function , moderate """,characteristic_level;characteristic_name,characteristic_name,"renal function , moderate """,characteristic_name
906,"race , non - white",characteristic_level;characteristic_name,characteristic_level,"race , non - white",characteristic_level
907,"hazard ratio """,measures;p-interaction,measures,"hazard ratio """,measures
909,hazard ratio,measures;p-interaction,measures,hazard ratio,measures
910,( nmbr % ci ),measures;p-interaction,measures,( nmbr % ci ),measures
914,patients with event / patients analyzed,measures;p-interaction,characteristic_level,patients with event / patients analyzed,characteristic_level
916,cangrelor,arms;measures;p-interaction,arms,cangrelor,arms
917,p interaction,arms;measures;p-interaction,characteristic_name,p interaction,characteristic_name
918,or ( nmbr % cl ),arms;measures;p-interaction,measures,or ( nmbr % cl ),measures
919,clopidogrel,arms;measures;p-interaction,arms,clopidogrel,arms
920,"or ( nmbr % cl ) """,arms;measures;p-interaction,measures,"or ( nmbr % cl ) """,measures
921,pbo ( n = nmbr ),arms;measures,arms,pbo ( n = nmbr ),arms
922,"brv nmbr mg / day ( n = nmbr ) """,arms;measures,arms,"brv nmbr mg / day ( n = nmbr ) """,arms
923,brv nmbr mg / day ( n = nmbr ),arms;measures,arms,brv nmbr mg / day ( n = nmbr ),arms
924,"outcome """,arms;outcomes;measures;p-interaction,outcomes,"outcome """,outcomes
925,hr ( nmbr % cl ),arms;outcomes;measures;p-interaction,measures,hr ( nmbr % cl ),measures
926,outcome,arms;outcomes;measures;p-interaction,outcomes,outcome,outcomes
927,p interaction,arms;outcomes;measures;p-interaction,characteristic_name,p interaction,characteristic_name
930,saxagliptin ( % ),arms;measures;p-interaction,arms,saxagliptin ( % ),arms
931,placebo ( % ),arms;measures;p-interaction,arms,placebo ( % ),arms
932,"saxagliptin ( % ) """,arms;measures;p-interaction,arms,"saxagliptin ( % ) """,arms
938,"placebo % """,arms;measures;p-interaction,arms,"placebo % """,arms
940,n,arms;measures;p-interaction,characteristic_name,n,characteristic_name
941,continued thienopyridine %,arms;measures;p-interaction,arms,continued thienopyridine %,arms
942,p value for interactiont,arms;measures;p-interaction,measures,p value for interactiont,measures
943,placebo %,arms;measures;p-interaction,arms,placebo %,arms
944,pvalue,arms;measures,measures,pvalue,measures
945,treatment arm,arms;measures,characteristic_name,treatment arm,characteristic_name
946,"treatment arm """,arms;measures,characteristic_name,"treatment arm """,characteristic_name
947,hazard ratio ( nmbr % confi dence interval ),arms;measures;p-interaction,measures,hazard ratio ( nmbr % confi dence interval ),measures
949,"hazard ratio ( nmbr % confi dence interval ) """,arms;measures;p-interaction,measures,"hazard ratio ( nmbr % confi dence interval ) """,measures
950,laa closure,arms;measures;p-interaction,characteristic_name,laa closure,characteristic_name
951,warfarin,arms;measures;p-interaction,arms,warfarin,arms
953,"subgroup """,arms;measures,characteristic_level,"subgroup """,characteristic_level
954,subgroup,arms;measures,characteristic_level,subgroup,characteristic_level
955,medical therapy ( n = nmbr ),arms;measures,characteristic_name,medical therapy ( n = nmbr ),characteristic_name
956,stent ( n = nmbr ),arms;measures,arms,stent ( n = nmbr ),arms
959,medical therapy,arms;measures,characteristic_name,medical therapy,characteristic_name
960,value,arms;measures,measures,value,measures
961,"value """,arms;measures,measures,"value """,measures
963,stent,arms;measures,characteristic_name,stent,characteristic_name
964,hazard ratio ( nmbr % cl ),arms;measures,measures,hazard ratio ( nmbr % cl ),measures
965,standard care n ( % ),arms;measures;p-interaction,arms,standard care n ( % ),arms
967,insulin glargine n ( x ),arms;measures;p-interaction,arms,insulin glargine n ( x ),arms
968,nmbr % cl,arms;measures;p-interaction,measures,nmbr % cl,measures
969,hazard ratio,arms;measures;p-interaction,measures,hazard ratio,measures
970,"standard care n ( % ) """,arms;measures;p-interaction,arms,"standard care n ( % ) """,arms
971,selexipag ( n = nmbr ),arms;measures,arms,selexipag ( n = nmbr ),arms
972,"selexipag ( n = nmbr ) """,arms;measures,arms,"selexipag ( n = nmbr ) """,arms
975,"change from baseline ( % ) """,measures;p-interaction,measures,"change from baseline ( % ) """,measures
976,change from baseline ( % ),measures;p-interaction,measures,change from baseline ( % ),measures
977,etd ( % ) [nmbr % ci],arms;p-interaction,measures,etd ( % ) [nmbr % ci],measures
978,"placebo ls means ( n ) """,arms;p-interaction,arms,"placebo ls means ( n ) """,arms
979,placebo ls means ( n ),arms;p-interaction,arms,placebo ls means ( n ),arms
980,liraglutide nmbr . nmbr mg ls means ( n ),arms;p-interaction,arms,liraglutide nmbr . nmbr mg ls means ( n ),arms
981,"ratio of hrs ( nmbr % ci ) , p for sex interaction",measures;p-interaction,characteristic_name,"ratio of hrs ( nmbr % ci ) , p for sex interaction",characteristic_name
982,no of events women men *,measures;p-interaction,characteristic_level,no of events women men *,characteristic_level
983,"ratio of hrs ( nmbr % ci ) , p for sex interaction """,measures;p-interaction,characteristic_name,"ratio of hrs ( nmbr % ci ) , p for sex interaction """,characteristic_name
984,no of events womenmen *,measures;p-interaction,measures,no of events womenmen *,measures
985,"ratio of hrs ( nmbr % cl ) , p for sex interaction",measures;p-interaction,characteristic_name,"ratio of hrs ( nmbr % cl ) , p for sex interaction",characteristic_name
986,"ratio of hrs ( nmbr % cl ) , p for sex interaction """,measures;p-interaction,characteristic_name,"ratio of hrs ( nmbr % cl ) , p for sex interaction """,characteristic_name
987,p value ( men versus women ),characteristic_level;measures,characteristic_level,p value ( men versus women ),characteristic_level
988,p value ( cangrelor versus clopidogrel in women ),characteristic_level;measures,arms,p value ( cangrelor versus clopidogrel in women ),arms
989,p value ( cangrelor versus clopidogrel in men ),characteristic_level;measures,arms,p value ( cangrelor versus clopidogrel in men ),arms
990,"men ( n = nmbr ) """,characteristic_level;measures,characteristic_level,"men ( n = nmbr ) """,characteristic_level
991,women ( n = nmbr ),characteristic_level;measures,characteristic_level,women ( n = nmbr ),characteristic_level
992,men ( n = nmbr ),characteristic_level;measures,characteristic_level,men ( n = nmbr ),characteristic_level
993,"nmbr - wk kaplan - meier rate , %",measures;p-interaction,measures,"nmbr - wk kaplan - meier rate , %",measures
994,"total no . """,measures;p-interaction,measures,"total no . """,measures
995,"events , no .",measures;p-interaction,measures,"events , no .",measures
997,total no .,measures;p-interaction,measures,total no .,measures
998,hazard ratio ( nmbr % cl ),measures;p-interaction,measures,hazard ratio ( nmbr % cl ),measures
999,"prior mi ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"prior mi ( n - nmbr , nmbr )",characteristic_level
1000,"any mi ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"any mi ( n - nmbr , nmbr )",characteristic_level
1001,"no mi ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"no mi ( n - nmbr , nmbr )",characteristic_level
1002,"index mi ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"index mi ( n - nmbr , nmbr )",characteristic_level
1003,"any mi ( n - nmbr , nmbr ) """,characteristic_level;measures,characteristic_level,"any mi ( n - nmbr , nmbr ) """,characteristic_level
1004,pvaluefor any mi versus no mi,characteristic_level;measures,characteristic_level,pvaluefor any mi versus no mi,characteristic_level
1005,"no diabetes ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"no diabetes ( n - nmbr , nmbr )",characteristic_level
1006,"diabetes ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"diabetes ( n - nmbr , nmbr )",characteristic_level
1007,"diabetes ( n - nmbr , nmbr ) """,characteristic_level;measures,characteristic_level,"diabetes ( n - nmbr , nmbr ) """,characteristic_level
1009,"pad ( n - nmbr , nmbr )",arms;measures,characteristic_level,"pad ( n - nmbr , nmbr )",characteristic_level
1010,"pad ( n - nmbr , nmbr ) """,arms;measures,characteristic_level,"pad ( n - nmbr , nmbr ) """,characteristic_level
1011,"no pad ( n - nmbr , nmbr )",arms;measures,characteristic_level,"no pad ( n - nmbr , nmbr )",characteristic_level
1013,"odds ratio ( nmbr % cl ) """,arms;measures,measures,"odds ratio ( nmbr % cl ) """,measures
1015,odds ratio ( nmbr % cl ),arms;measures,measures,odds ratio ( nmbr % cl ),measures
1016,rosuvastatin,arms;measures,arms,rosuvastatin,arms
1017,trend / het . test,arms;measures,characteristic_name,trend / het . test,characteristic_name
1018,heterogeneity test,arms;measures,characteristic_name,heterogeneity test,characteristic_name
1019,"percentage difference ( nmbr % cl ) """,arms;measures,measures,"percentage difference ( nmbr % cl ) """,measures
1022,percentage difference ( nmbr % cl ),arms;measures,measures,percentage difference ( nmbr % cl ),measures
1028,all patients n = nmbr,arms;measures,characteristic_level,all patients n = nmbr,characteristic_level
1029,pbo + mtx n = nmbr,arms;measures,arms,pbo + mtx n = nmbr,arms
1030,"czp + mtx n = nmbr """,arms;measures,arms,"czp + mtx n = nmbr """,arms
1031,czp + mtx n = nmbr,arms;measures,arms,czp + mtx n = nmbr,arms
1032,salmeterol - fluticasone group,measures;arms,arms,salmeterol - fluticasone group,arms
1033,"indacaterol - glycopyrronium group """,measures;arms,arms,"indacaterol - glycopyrronium group """,arms
1034,rate ratio ( nmbr % cl ),measures;arms,measures,rate ratio ( nmbr % cl ),measures
1035,indacaterol - glycopyrronium group,measures;arms,arms,indacaterol - glycopyrronium group,arms
1038,liraglutide,arms;measures,arms,liraglutide,arms
1039,hazard ratio,arms;measures,measures,hazard ratio,measures
1041,us ( n = nmbr ),arms;measures,arms,us ( n = nmbr ),arms
1043,non - us ( n = nmbr ),arms;measures,characteristic_level,non - us ( n = nmbr ),characteristic_level
1045,"p , treatment - by - region interaction",characteristic_level;p-interaction,characteristic_name,"p , treatment - by - region interaction",characteristic_name
1046,non - us ( n = nmbr ),characteristic_level;p-interaction,characteristic_level,non - us ( n = nmbr ),characteristic_level
1047,us ( n = nmbr ),characteristic_level;p-interaction,arms,us ( n = nmbr ),arms
1048,"p , regional difference",characteristic_level;p-interaction,measures,"p , regional difference",measures
1049,"non - us ( n = nmbr ) """,characteristic_level;p-interaction,characteristic_level,"non - us ( n = nmbr ) """,characteristic_level
1050,"or ( nmbr % ci ) """,arms;measures,other,"or ( nmbr % ci ) """,other
1051,clopidogrel,arms;measures,arms,clopidogrel,arms
1052,cangrelor,arms;measures,arms,cangrelor,arms
1053,or ( nmbr % ci ),arms;measures,other,or ( nmbr % ci ),other
1054,pfor interaction,measures;characteristic_level;p-interaction,characteristic_name,pfor interaction,characteristic_name
1055,central / eastern europe and russia hr ( nmbr % cl ),measures;characteristic_level;p-interaction,measures,central / eastern europe and russia hr ( nmbr % cl ),measures
1056,asia - pacific hr ( nmbr % cl ),measures;characteristic_level;p-interaction,measures,asia - pacific hr ( nmbr % cl ),measures
1057,latin america hr ( nmbr % cl ),measures;characteristic_level;p-interaction,measures,latin america hr ( nmbr % cl ),measures
1058,western europe hr ( nmbr % cl ),measures;characteristic_level;p-interaction,measures,western europe hr ( nmbr % cl ),measures
1059,overall hr ( nmbr % cl ),measures;characteristic_level;p-interaction,measures,overall hr ( nmbr % cl ),measures
1060,"central / eastern europe and russia hr ( nmbr % cl ) """,measures;characteristic_level;p-interaction,measures,"central / eastern europe and russia hr ( nmbr % cl ) """,measures
1061,north america hr ( nmbr % cl ),measures;characteristic_level;p-interaction,measures,north america hr ( nmbr % cl ),measures
1062,"< nmbr months in - nmbr kill """,characteristic_level;measures,arms,"< nmbr months in - nmbr kill """,arms
1063,"no prior hf hospitalization ( n = nmbr , nmbr )",characteristic_level;measures,characteristic_level,"no prior hf hospitalization ( n = nmbr , nmbr )",characteristic_level
1064,nmbr - nmbr months fn = nmbr . nmbr ),characteristic_level;measures,characteristic_level,nmbr - nmbr months fn = nmbr . nmbr ),characteristic_level
1065,nmbr - nmbr months ( n = nmbr ),characteristic_level;measures,characteristic_level,nmbr - nmbr months ( n = nmbr ),characteristic_level
1066,< nmbr months in - nmbr kill,characteristic_level;measures,arms,< nmbr months in - nmbr kill,arms
1067,"> nmbr months ( n = nmbr , nmbr )",characteristic_level;measures,characteristic_level,"> nmbr months ( n = nmbr , nmbr )",characteristic_level
1070,"event rates , %",measures;p-interaction,measures,"event rates , %",measures
1071,"event rates , % """,measures;p-interaction,measures,"event rates , % """,measures
1072,relative risk ( nmbr % ci ),measures;p-interaction,measures,relative risk ( nmbr % ci ),measures
1073,p - value for variance,measures;p-interaction,measures,p - value for variance,measures
1074,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr",characteristic_name;characteristic_level,characteristic_level,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr",characteristic_level
1075,ethnicitya hispanic or latino,characteristic_name;characteristic_level,characteristic_level,ethnicitya hispanic or latino,characteristic_level
1076,body mass indexa < median,characteristic_name;characteristic_level,characteristic_name,body mass indexa < median,characteristic_name
1077,< nmbr,characteristic_name;characteristic_level,characteristic_level,< nmbr,characteristic_level
1078,asia pacific and other,characteristic_name;characteristic_level,characteristic_level,asia pacific and other,characteristic_level
1080,age < median,characteristic_name;characteristic_level,characteristic_name,age < median,characteristic_name
1081,p - blocker yes,characteristic_name;characteristic_level,characteristic_level,p - blocker yes,characteristic_level
1082,racea white,characteristic_name;characteristic_level,characteristic_level,racea white,characteristic_level
1083,western europe,characteristic_name;characteristic_level,characteristic_level,western europe,characteristic_level
1085,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr a """,characteristic_name;characteristic_level,characteristic_level,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr a """,characteristic_level
1086,baseline heart failure severity nyha class i,characteristic_name;characteristic_level,characteristic_name,baseline heart failure severity nyha class i,characteristic_name
1087,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr a",characteristic_name;characteristic_level,characteristic_level,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr a",characteristic_level
1088,prior myocardial infarction yes,characteristic_name;characteristic_level,characteristic_level,prior myocardial infarction yes,characteristic_level
1089,> nmbr to < nmbr,characteristic_name;characteristic_level,characteristic_level,> nmbr to < nmbr,characteristic_level
1091,not hispanic or latino,characteristic_name;characteristic_level,characteristic_level,not hispanic or latino,characteristic_level
1092,prior hypertensiona yes,characteristic_name;characteristic_level,characteristic_level,prior hypertensiona yes,characteristic_level
1093,"> nmbr to < nmbr egfr , ml / min / nmbr . nmbr mnmbr a",characteristic_name;characteristic_level,characteristic_level,"> nmbr to < nmbr egfr , ml / min / nmbr . nmbr mnmbr a",characteristic_level
1094,prior congestive heart failure yes,characteristic_name;characteristic_level,characteristic_level,prior congestive heart failure yes,characteristic_level
1095,prior coronary artery disease yes,characteristic_name;characteristic_level,characteristic_level,prior coronary artery disease yes,characteristic_level
1096,thiazolidinedione yes,characteristic_name;characteristic_level,characteristic_level,thiazolidinedione yes,characteristic_level
1097,nyha class not reported,characteristic_name;characteristic_level,characteristic_name,nyha class not reported,characteristic_name
1101,none,characteristic_name;characteristic_level,characteristic_name,none,characteristic_name
1102,insulin yes,characteristic_name;characteristic_level,characteristic_level,insulin yes,characteristic_level
1103,region latin american,characteristic_name;characteristic_level,characteristic_name,region latin american,characteristic_name
1104,glycated hemoglobin < median,characteristic_name;characteristic_level,characteristic_name,glycated hemoglobin < median,characteristic_name
1105,"systolic blood pressure , mm hg < nmbr",characteristic_name;characteristic_level,characteristic_level,"systolic blood pressure , mm hg < nmbr",characteristic_level
1106,"renal function < nmbr egfr , ml / min / nmbr . nmbr mnmbr",characteristic_name;characteristic_level,characteristic_level,"renal function < nmbr egfr , ml / min / nmbr . nmbr mnmbr",characteristic_level
1107,diuretic thiazide,characteristic_name;characteristic_level,arms,diuretic thiazide,arms
1108,sexa male,characteristic_name;characteristic_level,characteristic_level,sexa male,characteristic_level
1109,> median,characteristic_name;characteristic_level,characteristic_level,> median,characteristic_level
1111,eastern europe,characteristic_name;characteristic_level,characteristic_level,eastern europe,characteristic_level
1112,north america,characteristic_name;characteristic_level,characteristic_level,north america,characteristic_level
1113,diabetes durationa < median,characteristic_name;characteristic_level,characteristic_level,diabetes durationa < median,characteristic_level
1114,nyha class > ii,characteristic_name;characteristic_level,characteristic_level,nyha class > ii,characteristic_level
1115,ace inhibitor yes,characteristic_name;characteristic_level,characteristic_level,ace inhibitor yes,characteristic_level
1116,angiotensin receptor blocker yes,characteristic_name;characteristic_level,characteristic_level,angiotensin receptor blocker yes,characteristic_level
1117,sitagliptin no . / total no .,arms;measures;p-interaction,arms,sitagliptin no . / total no .,arms
1119,placebo no . / total no .,arms;measures;p-interaction,arms,placebo no . / total no .,arms
1120,p value fo interactio,arms;measures;p-interaction,measures,p value fo interactio,measures
1121,"placebo no . / total no . """,arms;measures;p-interaction,arms,"placebo no . / total no . """,arms
1123,p - value *,arms;measures,measures,p - value *,measures
1124,"hr ( nmbr % cl ) """,arms;measures,measures,"hr ( nmbr % cl ) """,measures
1125,placebo events / n ( % ),arms;measures,arms,placebo events / n ( % ),arms
1126,pioglitazone events / n ( % ),arms;measures,measures,pioglitazone events / n ( % ),measures
1127,ticagrelor nmbr mg nmbr yr km %,arms;measures;p-interaction,arms,ticagrelor nmbr mg nmbr yr km %,arms
1128,placebo nmbr yr km %,arms;measures;p-interaction,arms,placebo nmbr yr km %,arms
1129,"placebo nmbr yr km % """,arms;measures;p-interaction,arms,"placebo nmbr yr km % """,arms
1130,ticagrelor nmbr mg vs . placebo hr ( nmbr % ci ),arms;measures;p-interaction,arms,ticagrelor nmbr mg vs . placebo hr ( nmbr % ci ),arms
1131,p - interaction,arms;measures;p-interaction,characteristic_name,p - interaction,characteristic_name
1132,p - interactio n,arms;measures;p-interaction,characteristic_name,p - interactio n,characteristic_name
1133,number of patients,arms;measures;p-interaction,measures,number of patients,measures
1134,hazard ratio ( nmbr % ci ),arms;p-interaction;measures,measures,hazard ratio ( nmbr % ci ),measures
1135,p interaction,arms;p-interaction;measures,characteristic_name,p interaction,characteristic_name
1136,monitoring treatment,arms;p-interaction;measures,arms,monitoring treatment,arms
1137,"p interaction """,arms;p-interaction;measures,characteristic_name,"p interaction """,characteristic_name
1138,conventional treatment,arms;p-interaction;measures,characteristic_name,conventional treatment,characteristic_name
1142,p - value,arms;measures,measures,p - value,measures
1143,"stent """,arms;measures,characteristic_name,"stent """,characteristic_name
1144,"stable angina ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"stable angina ( n - nmbr , nmbr )",characteristic_level
1145,"acs ( n - nmbr , nmbr ) """,characteristic_level;measures,characteristic_level,"acs ( n - nmbr , nmbr ) """,characteristic_level
1146,"acs ( n - nmbr , nmbr )",characteristic_level;measures,characteristic_level,"acs ( n - nmbr , nmbr )",characteristic_level
1148,statin non - users ( n = nmbr ),arms;measures,characteristic_level,statin non - users ( n = nmbr ),characteristic_level
1149,"statin non - users ( n = nmbr ) """,arms;measures,characteristic_level,"statin non - users ( n = nmbr ) """,characteristic_level
1150,statin users ( n = nmbr ),arms;measures,arms,statin users ( n = nmbr ),arms
1158,peripheral revascularization ( n = nmbr ),arms;measures,characteristic_level,peripheral revascularization ( n = nmbr ),characteristic_level
1159,"no peripheral revascularization ( n = nmbr , nmbr ) """,arms;measures,characteristic_level,"no peripheral revascularization ( n = nmbr , nmbr ) """,characteristic_level
1160,"no peripheral revascularization ( n = nmbr , nmbr )",arms;measures,characteristic_level,"no peripheral revascularization ( n = nmbr , nmbr )",characteristic_level
1162,adjusted hr ( enl vs lcz ) ( nmbr % cl ),arms;measures,measures,adjusted hr ( enl vs lcz ) ( nmbr % cl ),measures
1164,"patients receiving enl , no . ( % )",arms;measures,characteristic_level,"patients receiving enl , no . ( % )",characteristic_level
1165,incidencea,arms;measures,characteristic_name,incidencea,characteristic_name
1166,hr ( enl vs lcz ) ( nmbr % cl ),arms;measures,measures,hr ( enl vs lcz ) ( nmbr % cl ),measures
1167,"patients receiving lcz , no . ( % )",arms;measures,characteristic_level,"patients receiving lcz , no . ( % )",characteristic_level
1170,nmbr mg sirukumab every nmbr weeks ( n = nmbr ),arms;measures,arms,nmbr mg sirukumab every nmbr weeks ( n = nmbr ),arms
1173,pioglitazone pts / n ( % ),arms;measures,characteristic_name,pioglitazone pts / n ( % ),characteristic_name
1174,placebo pts / n ( % ),arms;measures,arms,placebo pts / n ( % ),arms
1176,"pioglitazone pts / n ( % ) """,arms;measures,characteristic_name,"pioglitazone pts / n ( % ) """,characteristic_name
1178,"copd - placebo ( n = nmbr ) """,arms;measures,arms,"copd - placebo ( n = nmbr ) """,arms
1179,copd - placebo ( n = nmbr ),arms;measures,arms,copd - placebo ( n = nmbr ),arms
1180,copd ( n = nmbr ),arms;measures,characteristic_name,copd ( n = nmbr ),characteristic_name
1182,copd - rosuvastatin ( n = nmbr ),arms;measures,arms,copd - rosuvastatin ( n = nmbr ),arms
1183,"adjusted """,arms;measures,arms,"adjusted """,arms
1184,adjusted,arms;measures,arms,adjusted,arms
1185,unadjusted,arms;measures,characteristic_name,unadjusted,characteristic_name
1187,"abatacept / open - label abatacept """,arms;measures,arms,"abatacept / open - label abatacept """,arms
1188,estimated difference ( nmbr % ci ),arms;measures,measures,estimated difference ( nmbr % ci ),measures
1189,abatacept,arms;measures,arms,abatacept,arms
1190,placebo / open - label abatacept,arms;measures,arms,placebo / open - label abatacept,arms
1191,abatacept / open - label abatacept,arms;measures,arms,abatacept / open - label abatacept,arms
1192,hazard ratio ( nmbr % ci ),arms;measures;p-interaction,measures,hazard ratio ( nmbr % ci ),measures
1193,"canagliflozin """,arms;measures;p-interaction,characteristic_name,"canagliflozin """,characteristic_name
1194,placebo,arms;measures;p-interaction,arms,placebo,arms
1195,canagliflozin,arms;measures;p-interaction,characteristic_name,canagliflozin,characteristic_name
1197,treatment difference,arms;measures,measures,treatment difference,measures
1200,linagliptin,arms;measures,arms,linagliptin,arms
1202,or ( nmbr % ci ),arms;measures;p-interaction,other,or ( nmbr % ci ),other
1203,"clopidogrel , %",arms;measures;p-interaction,arms,"clopidogrel , %",arms
1204,p value ( int ),arms;measures;p-interaction,measures,p value ( int ),measures
1205,"cangrelor , % """,arms;measures;p-interaction,arms,"cangrelor , % """,arms
1206,"cangrelor , %",arms;measures;p-interaction,arms,"cangrelor , %",arms
1207,"hazard ratio for cardiovascular death , stroke , or myocardial infarction ( nmbr % ci )",arms;measures;p-interaction,outcomes,"hazard ratio for cardiovascular death , stroke , or myocardial infarction ( nmbr % ci )",outcomes
1208,rivaroxaban + aspirin,arms;measures;p-interaction,arms,rivaroxaban + aspirin,arms
1209,aspirin alone,arms;measures;p-interaction,arms,aspirin alone,arms
1211,"rivaroxaban + aspirin """,arms;measures;p-interaction,arms,"rivaroxaban + aspirin """,arms
1212,ppci ( n = nmbr ),arms;measures,characteristic_level,ppci ( n = nmbr ),characteristic_level
1214,"ppci ( n = nmbr ) """,arms;measures,characteristic_level,"ppci ( n = nmbr ) """,characteristic_level
1215,phi ( n = nmbr ),arms;measures,characteristic_level,phi ( n = nmbr ),characteristic_level
1217,phi ( n - nmbr ),arms;measures,characteristic_level,phi ( n - nmbr ),characteristic_level
1218,( nmbr % cl ),arms;measures,measures,( nmbr % cl ),measures
1219,rr,arms;measures,characteristic_name,rr,characteristic_name
1220,"( nmbr % cl ) """,arms;measures,measures,"( nmbr % cl ) """,measures
1221,ppci in - nmbr,arms;measures,arms,ppci in - nmbr,arms
1222,rate ratio,arms;measures;p-interaction,measures,rate ratio,measures
1223,non - hdl - c,arms;measures;p-interaction,outcomes,non - hdl - c,outcomes
1224,hdl - c,arms;measures;p-interaction,characteristic_name,hdl - c,characteristic_name
1226,anacetrapib ( n = nmbr ),arms;measures;p-interaction,arms,anacetrapib ( n = nmbr ),arms
1227,"non - hdl - c """,arms;measures;p-interaction,outcomes,"non - hdl - c """,outcomes
1228,p - value interaction,arms;measures;p-interaction,measures,p - value interaction,measures
1229,baseline,measures;other,characteristic_name,baseline,characteristic_name
1230,monthnmbr,measures;other,characteristic_name,monthnmbr,characteristic_name
1231,month nmbr,measures;other,characteristic_name,month nmbr,characteristic_name
1232,"month nmbr """,measures;other,characteristic_name,"month nmbr """,characteristic_name
1233,tiotropium,arms;measures,arms,tiotropium,arms
1236,difference ( tiotropium - placebo ) ml ( nmbr % ci ),arms;measures,arms,difference ( tiotropium - placebo ) ml ( nmbr % ci ),arms
1237,p values,arms;measures,characteristic_name,p values,characteristic_name
1239,"rate ratio ( nmbr % cl ) """,measures;arms,measures,"rate ratio ( nmbr % cl ) """,measures
1240,mepolizumab group,measures;arms,arms,mepolizumab group,arms
1241,placebo group,measures;arms,arms,placebo group,arms
1242,ldl particle numbers ( week nmbr ),measures;outcomes,measures,ldl particle numbers ( week nmbr ),measures
1243,calculated ldl cholesterol ( week nmbr ),measures;outcomes,characteristic_name,calculated ldl cholesterol ( week nmbr ),characteristic_name
1244,total cholesterol ( week nmbr ),measures;outcomes,characteristic_name,total cholesterol ( week nmbr ),characteristic_name
1245,hdl cholesterol ( week nmbr ) a,measures;outcomes,characteristic_name,hdl cholesterol ( week nmbr ) a,characteristic_name
1246,apob ( week nmbr ),measures;outcomes,outcomes,apob ( week nmbr ),outcomes
1247,ldl particle size ( week nmbr ),measures;outcomes,measures,ldl particle size ( week nmbr ),measures
1248,ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr,measures;outcomes,measures,ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr,measures
1249,lp ( a ) ( week nmbr ),measures;outcomes,measures,lp ( a ) ( week nmbr ),measures
1250,"mmol / l """,measures;outcomes,characteristic_level,"mmol / l """,characteristic_level
1251,mmol / l,measures;outcomes,characteristic_level,mmol / l,characteristic_level
1252,triglycerides ( week nmbr ) a,measures;outcomes,measures,triglycerides ( week nmbr ) a,measures
1253,non - hdl cholesterol ( week nmbr ),measures;outcomes,characteristic_name,non - hdl cholesterol ( week nmbr ),characteristic_name
1254,mg / dl,measures;outcomes,arms,mg / dl,arms
1255,total ( n = nmbr ),measures;arms,arms,total ( n = nmbr ),arms
1256,"total ( n = nmbr ) """,measures;arms,arms,"total ( n = nmbr ) """,arms
1257,ertugliflozin nmbr mg ( n = nmbr ),measures;arms,arms,ertugliflozin nmbr mg ( n = nmbr ),arms
1258,placebo ( n = nmbr ),measures;arms,arms,placebo ( n = nmbr ),arms
1259,change in sbp ( nmbr months ),outcomes;measures,arms,change in sbp ( nmbr months ),arms
1260,first hhf,outcomes;measures,characteristic_name,first hhf,characteristic_name
1261,kccq ( nmbr months ),outcomes;measures,arms,kccq ( nmbr months ),arms
1262,death ( all - cause ),outcomes;measures,outcomes,death ( all - cause ),outcomes
1263,"months ( log - transformed ) """,outcomes;measures,characteristic_name,"months ( log - transformed ) """,characteristic_name
1264,change in nt - probnp at nmbr months ( log - transformed ),outcomes;measures,arms,change in nt - probnp at nmbr months ( log - transformed ),arms
1265,cv death or first hhf,outcomes;measures,outcomes,cv death or first hhf,outcomes
1266,months ( log - transformed ),outcomes;measures,characteristic_name,months ( log - transformed ),characteristic_name
1267,cv death,outcomes;measures,outcomes,cv death,outcomes
1268,"no stroke ( n = nmbr ) """,outcomes;other,characteristic_level,"no stroke ( n = nmbr ) """,characteristic_level
1269,p value,outcomes;other,measures,p value,measures
1270,no stroke ( n = nmbr ),outcomes;other,characteristic_level,no stroke ( n = nmbr ),characteristic_level
1271,any stroke ( n = nmbr ),outcomes;other,outcomes,any stroke ( n = nmbr ),outcomes
1272,hr ( nmbr % ci ),arms;other;p-interaction,measures,hr ( nmbr % ci ),measures
1273,p - int,arms;other;p-interaction,characteristic_name,p - int,characteristic_name
1274,ez / simva < % >,arms;other;p-interaction,arms,ez / simva < % >,arms
1275,total patients,arms;other;p-interaction,measures,total patients,measures
1276,"p - int """,arms;other;p-interaction,characteristic_name,"p - int """,characteristic_name
1277,simva ( % ),arms;other;p-interaction,arms,simva ( % ),arms
1278,prior stroke,characteristic_name;p-interaction,characteristic_level,prior stroke,characteristic_level
1279,"no prior stroke """,characteristic_name;p-interaction,characteristic_level,"no prior stroke """,characteristic_level
1280,no prior stroke,characteristic_name;p-interaction,characteristic_level,no prior stroke,characteristic_level
1281,p interaction,characteristic_name;p-interaction,characteristic_name,p interaction,characteristic_name
1282,arr ( nmbr % cl ),arms;measures,measures,arr ( nmbr % cl ),measures
1283,"simva n = nmbr n ( % ) """,arms;measures,arms,"simva n = nmbr n ( % ) """,arms
1285,simva n = nmbr n ( % ),arms;measures,arms,simva n = nmbr n ( % ),arms
1286,ez / simva n = nmbr n ( % ),arms;measures,arms,ez / simva n = nmbr n ( % ),arms
1288,risk difference,arms;measures,measures,risk difference,measures
1289,pioglitazone,arms;measures,characteristic_name,pioglitazone,characteristic_name
1291,"complex anatomy ( n - nmbr , nmbr )",arms;other,arms,"complex anatomy ( n - nmbr , nmbr )",arms
1292,"noncomplex anatomy ( n - nmbr , nmbr )",arms;other,characteristic_level,"noncomplex anatomy ( n - nmbr , nmbr )",characteristic_level
1293,"complex anatomy ( n - nmbr , nmbr ) """,arms;other,arms,"complex anatomy ( n - nmbr , nmbr ) """,arms
1296,"placebo """,arms;measures;p-interaction,arms,"placebo """,arms
1297,int . p *,arms;measures;p-interaction,characteristic_name,int . p *,characteristic_name
1298,pioglitazone,arms;measures;p-interaction,characteristic_name,pioglitazone,characteristic_name
1300,hr ( nmbr % ci ),arms;p-interaction,measures,hr ( nmbr % ci ),measures
1301,low - dose rivaroxaban + aspirin ( n / n ),arms;p-interaction,arms,low - dose rivaroxaban + aspirin ( n / n ),arms
1302,"hr ( nmbr % ci ) """,arms;p-interaction,measures,"hr ( nmbr % ci ) """,measures
1303,aspirin alone ( n / n ),arms;p-interaction,arms,aspirin alone ( n / n ),arms
1304,pinteraction,arms;p-interaction,characteristic_name,pinteraction,characteristic_name
1305,"aspirin alone group no of events / total n ( % ) """,arms;p-interaction;measures,arms,"aspirin alone group no of events / total n ( % ) """,arms
1306,hr ( nmbr % ci ),arms;p-interaction;measures,measures,hr ( nmbr % ci ),measures
1307,aspirin alone group no of events / total n ( % ),arms;p-interaction;measures,arms,aspirin alone group no of events / total n ( % ),arms
1308,pinteraction,arms;p-interaction;measures,characteristic_name,pinteraction,characteristic_name
1309,low - dose rivaroxaban + aspirin group,arms;p-interaction;measures,arms,low - dose rivaroxaban + aspirin group,arms
1310,"placebo ,",measures;arms,arms,"placebo ,",arms
1311,etd ( nmbr % ci ),measures;arms,measures,etd ( nmbr % ci ),measures
1312,"etd ( nmbr % ci ) """,measures;arms,measures,"etd ( nmbr % ci ) """,measures
1313,"liraglutide nmbr . nmbr mg ,",measures;arms,arms,"liraglutide nmbr . nmbr mg ,",arms
1314,liraglutide nmbr . nmbr mg,arms;measures,arms,liraglutide nmbr . nmbr mg,arms
1315,"placebo ,",arms;measures,arms,"placebo ,",arms
1316,"liraglutide nmbr . nmbr mg ,",arms;measures,arms,"liraglutide nmbr . nmbr mg ,",arms
1317,etd ( nmbr % ci ),arms;measures,measures,etd ( nmbr % ci ),measures
1318,"etd ( nmbr % ci ) """,arms;measures,measures,"etd ( nmbr % ci ) """,measures
1319,pbo / simva - nmbryr km rale ( % ),arms;measures,arms,pbo / simva - nmbryr km rale ( % ),arms
1320,hr ( nmbr % ci ),arms;measures,measures,hr ( nmbr % ci ),measures
1321,"eze / simva - nmbryr km rale ( % ) """,arms;measures,arms,"eze / simva - nmbryr km rale ( % ) """,arms
1322,eze / simva - nmbryr km rale ( % ),arms;measures,arms,eze / simva - nmbryr km rale ( % ),arms
1323,placebo / simvastatin,arms;p-interaction;other,arms,placebo / simvastatin,arms
1324,pin /,arms;p-interaction;other,characteristic_name,pin /,characteristic_name
1325,ezetimibe / simvastatin,arms;p-interaction;other,arms,ezetimibe / simvastatin,arms
1326,p value *,arms;p-interaction;other,measures,p value *,measures
1327,"pin / """,arms;p-interaction;other,characteristic_name,"pin / """,characteristic_name
1328,placebo / simvastatin,arms;measures;p-interaction,arms,placebo / simvastatin,arms
1329,pin /,arms;measures;p-interaction,characteristic_name,pin /,characteristic_name
1330,ezetimibe / simvastatin,arms;measures;p-interaction,arms,ezetimibe / simvastatin,arms
1331,p value *,arms;measures;p-interaction,measures,p value *,measures
1332,"pin / """,arms;measures;p-interaction,characteristic_name,"pin / """,characteristic_name
1333,"diabetes present nmbr ( nmbr . nmbr ) """,arms;measures,characteristic_level,"diabetes present nmbr ( nmbr . nmbr ) """,characteristic_level
1334,diabetes absent nmbr ( nmbr . nmbr ),arms;measures,characteristic_level,diabetes absent nmbr ( nmbr . nmbr ),characteristic_level
1335,diabetes present nmbr ( nmbr . nmbr ),arms;measures,characteristic_level,diabetes present nmbr ( nmbr . nmbr ),characteristic_level
1340,"placebo / simvastatin """,arms;measures;p-interaction,arms,"placebo / simvastatin """,arms
1342,"no mvd ( n - nmbr , nmbr ) """,arms;other,characteristic_level,"no mvd ( n - nmbr , nmbr ) """,characteristic_level
1344,"mvd ( n - nmbr , nmbr )",arms;other,characteristic_level,"mvd ( n - nmbr , nmbr )",characteristic_level
1345,"no mvd ( n - nmbr , nmbr )",arms;other,characteristic_level,"no mvd ( n - nmbr , nmbr )",characteristic_level
1346,"ef nmbr - nmbr % hfmref ( n = nmbr , nmbr % )",arms;measures,characteristic_level,"ef nmbr - nmbr % hfmref ( n = nmbr , nmbr % )",characteristic_level
1347,"ef < nmbr % hfref ( n = nmbr , nmbr % )",arms;measures,characteristic_level,"ef < nmbr % hfref ( n = nmbr , nmbr % )",characteristic_level
1348,p - value for trend *,arms;measures,measures,p - value for trend *,measures
1349,"ef > nmbr % hfpef ( n = nmbr , nmbr % )",arms;measures,characteristic_level,"ef > nmbr % hfpef ( n = nmbr , nmbr % )",characteristic_level
1350,"p - value for trend * """,arms;measures,measures,"p - value for trend * """,measures
1351,ef < nmbr %,characteristic_name;p-interaction,arms,ef < nmbr %,arms
1352,p - interaction,characteristic_name;p-interaction,characteristic_name,p - interaction,characteristic_name
1353,"ef > nmbr % """,characteristic_name;p-interaction,arms,"ef > nmbr % """,arms
1354,ef nmbr - nmbr %,characteristic_name;p-interaction,characteristic_level,ef nmbr - nmbr %,characteristic_level
1355,ef > nmbr %,characteristic_name;p-interaction,arms,ef > nmbr %,arms
